US20050112175A1 - Drug delivery device - Google Patents
Drug delivery device Download PDFInfo
- Publication number
- US20050112175A1 US20050112175A1 US10/957,910 US95791004A US2005112175A1 US 20050112175 A1 US20050112175 A1 US 20050112175A1 US 95791004 A US95791004 A US 95791004A US 2005112175 A1 US2005112175 A1 US 2005112175A1
- Authority
- US
- United States
- Prior art keywords
- drug delivery
- pharmaceutically active
- inner core
- delivery device
- active agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00885—Methods or devices for eye surgery using laser for treating a particular disease
- A61F2009/00891—Glaucoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
Definitions
- the present invention generally pertains to biocompatible implants for localized delivery of pharmaceutically active agents to body tissue. More particularly, but not by way of limitation, the present invention pertains to biocompatible implants for localized delivery of pharmaceutically active agents to the posterior segment of the eye.
- Age related macular degeneration choroidal neovascularization (CNV), retinopathies (i.e. diabetic retinopathy, vitreoretinopathy), retinitis (i.e. cytomegalovirus (CMV) retinitis), uveitis, macular edema, and glaucoma are several examples.
- AMD Age related macular degeneration
- CNV choroidal neovascularization
- retinopathies i.e. diabetic retinopathy, vitreoretinopathy
- retinitis i.e. cytomegalovirus (CMV) retinitis
- uveitis macular edema
- macular edema glaucoma
- Age related macular degeneration is the leading cause of blindness in the elderly. ARMD attacks the center of vision and blurs it, making reading, driving, and other detailed tasks difficult or impossible. About 200,000 new cases of ARMD occur each year in the United States alone. Current estimates reveal that approximately forty percent of the population over age 75 , and approximately twenty percent of the population over age 60 , suffer from some degree of macular degeneration. “Wet” ARMD is the type of ARMD that most often causes blindness. In wet ARMD, newly formed choroidal blood vessels (choroidal neovascularization (CNV)) leak fluid and cause progressive damage to the retina.
- CNV choroidal neovascularization
- CNV in ARMD two main methods of treatment are currently being developed, (a) photocoagulation and (b) the use of angiogenesis inhibitors.
- photocoagulation can be harmful to the retina and is impractical when the CNV is near the fovea.
- photocoagulation often results in recurrent CNV over time.
- Oral or parenteral (non-ocular) administration of anti-angiogenic compounds is also being tested as a systemic treatment for ARMD.
- systemic administration usually provides sub-therapeutic drug levels to the eye. Therefore, to achieve effective intraocular drug concentrations, either an unacceptably high dose or repetitive conventional doses are required.
- Periocular injections of these compounds often result in the drug being quickly washed out and depleted from the eye, via periocular vasculature and soft tissue, into the general circulation. Repetitive intraocular injections may result in severe, often blinding, complications such as retinal detachment and endophthalmitis.
- U.S. Pat. No. 5,824,072 to Wong discloses a non-biodegradable polymeric implant with a pharmaceutically active agent disposed therein.
- the pharmaceutically active agent diffuses through the polymer body of the implant into the target tissue.
- the pharmaceutically active agent may include drugs for the treatment of macular degeneration and diabetic retinopathy.
- the implant is placed substantially within the tear fluid upon the outer surface of the eye over an avascular region, and may be anchored in the conjunctiva or sclera; episclerally or intrasclerally over an avascular region; substantially within the suprachoroidial space over an avascular region such as the pars plana or a surgically induced avascular region; or in direct communication with the vitreous.
- U.S. Pat. No. 5,476,511 to Gwon et al. discloses a polymer implant for placement under the conjunctiva of the eye.
- the implant may be used to deliver neovascular inhibitors for the treatment of ARMD and drugs for the treatment of retinopathies, retinitis, and CMV retinitis.
- the pharmaceutically active agent diffuses through the polymer body of the implant.
- U.S. Pat. No. 5,773,019 to Ashton et al. discloses a non-bioerodable polymer implant for delivery of certain drugs including angiostatic steroids and drugs such as cyclosporine for the treatment of uveitis. Once again, the pharmaceutically active agent diffuses through the polymer body of the implant.
- implants require careful design and manufacture to permit controlled diffusion of the pharmaceutically active agent through a polymer body (matrix devices) or polymer membrane (reservoir devices) to the desired site of therapy. Drug release from these devices depends on the porosity and diffusion characteristics of the matrix or membrane, respectively. These parameters must be tailored for each drug moiety to be used with these devices. Consequently, these requirements generally increase the complexity and cost of such implants.
- U.S. Pat. No. 5,824,073 to Peyman discloses an indentor for positioning in the eye.
- the indentor has a raised portion that is used to indent or apply pressure to the sclera over the macular area of the eye.
- This patent discloses that such pressure decreases choroidal congestion and blood flow through the subretinal neovascular membrane, which, in turn, decreases bleeding and subretinal fluid accumulation.
- the surgical procedure for implanting such a device should be safe, simple, quick, and capable of being performed in an outpatient setting.
- such a device should be easy and economical to manufacture.
- such an implant should be capable of use in clinical studies to deliver various agents that create a specific physical condition in a patient or animal subject.
- such an implantable drug delivery device is especially needed for localized delivery of pharmaceutically active agents to the posterior segment of the eye to combat ARMD, CNV, retinopathies, retinitis, uveitis, macular edema, and glaucoma.
- One aspect of the present invention comprises a drug delivery device including a body having an internal surface for placement proximate a target tissue and a well having an opening to the internal surface.
- An inner core comprising a pharmaceutically active agent is disposed in the well.
- the present invention comprises a method of delivering a pharmaceutically active agent to a target tissue within a body.
- a drug delivery device is provided.
- the drug delivery device includes a body having an internal surface and a well having an opening to the internal surface, and an inner core disposed in the well comprising a pharmaceutically active agent.
- the device is disposed within the body so that the pharmaceutically active agent is in communication with the target tissue through the opening.
- the present invention comprises an ophthalmic drug delivery device including a body having a scleral surface for placement proximate a sclera and a well or cavity having an opening to the scleral surface.
- An inner core comprising a pharmaceutically active agent is disposed in the well.
- the present invention comprises a method of delivering a pharmaceutically active agent to an eye having a sclera.
- a drug delivery device is provided.
- the drug delivery device includes a body having a scleral surface and a well having an opening to the scleral surface, and an inner core disposed in the well comprising a pharmaceutically active agent.
- the device is disposed within the eye so that the pharmaceutically active agent is in communication with the sclera through the opening.
- the present invention comprises a method of delivering a pharmaceutically active agent to an eye having a sclera, a Tenon's capsule, and a macula.
- a drug delivery device comprising a body having a pharmaceutically active agent disposed therein is provided. The device is disposed on an outer surface of the sclera, below the Tenon's capsule, and proximate the macula.
- FIG. 1 is a side sectional view of a drug delivery device according to a preferred embodiment of the present invention
- FIG. 2 is a side sectional view of a second drug delivery device according to a preferred embodiment of the present invention.
- FIG. 3 is a side sectional view schematically illustrating the human eye
- FIG. 4 is detailed cross-sectional view of the eye of FIG. 3 along line 4 - 4 ;
- FIG. 5 is a perspective view of an ophthalmic drug delivery device according to a preferred embodiment of the present invention.
- FIG. 6A is a side sectional view of the ophthalmic drug delivery device of FIG. 5 ;
- FIG. 6B is an enlarged cross-sectional view of the ophthalmic drug delivery device of FIG. 6A taken along line 6 B- 6 B;
- FIG. 7 is a graphical illustration of the results of a pharmacokinetic study with New Zealand White rabbits implanted with the ophthalmic drug delivery device of FIGS. 5 through 6 B showing the mean concentration of a pharmaceutically active agent at a target site in the retina and choroid of the rabbits as a function of time.
- FIGS. 1 through 7 of the drawings like numerals being used for like and corresponding parts of the various drawings.
- FIG. 1 schematically illustrates a drug delivery device 10 according to a preferred embodiment of the present invention.
- Device 10 may be used in any case where localized delivery of a pharmaceutically active agent to body tissue is required.
- device 10 may be used to treat a medical disorder of the eye, ear, nose, throat, skin, subcutaneous tissue, or bone.
- Device 10 may be used in humans or animals.
- Device 10 generally includes a body 12 having an internal surface 14 and an external surface 16 .
- body 12 preferably has a generally rectangular three-dimensional geometry with a proximal end 18 and a distal end 20 .
- Body 12 may have any other geometry that has an internal surface 14 for placement proximate a target tissue in the body of a patient.
- body 12 may have a cylindrical, an oval, a square, or other polygonal three-dimensional geometry.
- Body 12 includes a well or cavity 22 having an opening 24 to internal surface 14 .
- An inner core 26 is preferably disposed in well 22 .
- Inner core 26 is preferably a tablet comprising one or more pharmaceutically active agents.
- inner core 26 may comprise a conventional hydrogel having one or more pharmaceutically active agents disposed therein.
- a retaining member 28 is preferably disposed proximate opening 24 . Retaining member 28 prevents inner core 26 from falling out of well 22 .
- retaining member 28 is preferably a continuous rim or lip disposed circumferentially around opening 24 having a diameter slightly less than the diameter of tablet 26 .
- retaining member 26 may comprise one or more members that extend from body 12 into opening 24 .
- inner core 26 may alternatively comprise a suspension, solution, powder, or combination thereof containing one or more pharmaceutically active agents.
- internal surface 14 is formed without opening 24 , and the suspension, solution, powder, or combination thereof diffuses through the relatively thin portion of internal surface 14 below inner core 26 .
- device 10 may be formed without well 22 or inner core 26 , and the pharmaceutically active agent(s) in the form of a suspension, solution, powder, or combination thereof may be dispersed throughout body 12 of device 10 .
- the pharmaceutically active agent diffuses through body 12 into the target tissue.
- the geometry of device 10 maximizes communication between the pharmaceutically active agent of inner core 26 and the tissue underlying internal surface 14 .
- Internal surface 14 preferably physically contacts the target tissue.
- the target tissue has a generally flat surface
- device 10 would be appropriate for the delivery of a pharmaceutically active agent.
- a device 10 a shown in FIG. 2 having a generally concave internal surface 14 a designed to mate with such a target surface may be utilized. Corners 30 of proximal end 18 a , and corners 32 of distal end 20 a , may be slanted and/or rounded off to facilitate surgical placement of device 10 a and to maximize comfort to the patient.
- Retaining member 28 is preferably designed with a minimum thickness necessary to retain inner core 26 so as to dispose a surface 26 a of inner core 26 in close proximity to the target tissue.
- inner core 26 may be formed so that surface 26 a physically contacts the target tissue.
- device 10 or 10 a may be disposed in the body of a patient so that internal surface 14 or 14 a is disposed proximate the target tissue.
- internal surface 14 or 14 a physically contacts intermediate tissue disposed between it and the target tissue.
- the pharmaceutically active agent of inner core 26 communicates with the target tissue through opening 24 and this intermediate tissue.
- body 12 preferably comprises a biocompatible, non-bioerodable material.
- Body 12 more preferably comprises a biocompatible, non-bioerodable polymeric composition.
- Said polymeric composition may be a homopolymer, a copolymer, straight, branched, cross-linked, or a blend.
- polymers suitable for use in said polymeric composition include silicone, polyvinyl alcohol, ethylene vinyl acetate, polylactic acid, nylon, polypropylene, polycarbonate, cellulose, cellulose acetate, polyglycolic acid, polylactic-glycolic acid, cellulose esters, polyethersulfone, acrylics, their derivatives, and combinations thereof.
- suitable soft acrylics are more fully disclosed in U.S. Pat.
- Said polymeric composition most preferably comprises silicone.
- said polymeric composition may also comprise other conventional materials that affect its physical properties, including, but not limited to, porosity, tortuosity, permeability, rigidity, hardness, and smoothness. Exemplary materials affecting certain ones of these physical properties include conventional plasticizers, fillers, and lubricants.
- Said polymeric composition may comprise other conventional materials that affect its chemical properties, including, but not limited to, toxicity, hydrophobicity, and body 12 —inner core 26 interaction. Body 12 is preferably impermeable to the pharmaceutically active agent of inner core 26 .
- the diameter of well 22 may be slightly less than the diameter of inner core 26 . This frictional fit secures inner core 26 within well 22 .
- body 12 may be formed without retaining member 28 , if desired.
- Inner core 26 may comprise any pharmaceutically active agents suitable for localized delivery to a target tissue.
- pharmaceutically active agents suitable for inner core 26 are anti-infectives, including, without limitation, antibiotics, antivirals, and antifungals; antiallergenic agents and mast cell stabilizers; steroidal and non-steroidal anti-inflammatory agents; combinations of anti-infective and anti-inflammatory agents; decongestants; anti-glaucoma agents, including, without limitation, adrenergics, ⁇ -adrenergic blocking agents, ⁇ -adrenergic agonists, parasypathomimetic agents, cholinesterase inhibitors, carbonic anhydrase inhibitors, and prostaglandins; combinations of anti-glaucoma agents; antioxidants; nutritional supplements; drugs for the treatment of cystoid macular edema including, without limitation, non-steroidal anti-inflammatory agents; drugs for the treatment of ARMD, including, without limitation, angiogenesis inhibitors and nutritional supplements; drugs for the treatment of herpetic infections
- angiostatic steroids are more fully disclosed in U.S. Pat. Nos. 5,679,666 and 5,770,592, which are incorporated herein in their entirety by reference.
- Preferred ones of such angiostatic steroids include 4,9(11)-Pregnadien-17 ⁇ ,21-diol-3,20-dione and 4,9(11)-Pregnadien-17 ⁇ ,21-diol-3,20-dione-21-acetate.
- Inner core 26 may also comprise conventional non-active excipients to enhance the stability, solubility, penetrability, or other properties of the active agent or the drug core.
- inner core 26 is a tablet, it may further comprise conventional excipients necessary for tableting, such as fillers and lubricants. Such tablets may be produced using conventional tableting methods.
- the pharmaceutically active agent is preferably distributed evenly throughout the tablet.
- inner core 26 may comprise a special tablet that bioerodes at a controlled rate, releasing the pharmaceutically active agent. By way of example, such bioerosion may occur through hydrolosis or enzymatic cleavage.
- inner core 26 is a hydrogel, the hydrogel may bioerode at a controlled rate, releasing the pharmaceutically active agent. Alternatively, the hydrogel may be non-bioerodable but allow diffusion of the pharmaceutically active agent.
- Device 10 may be made by conventional polymer processing methods, including, but not limited to, injection molding, extrusion molding, transfer molding, and compression molding. Preferably, device 10 is formed using conventional injection molding techniques. Inner core 26 is preferably disposed in well 22 after the formation of body 12 of device 10 . Retaining member 28 is preferably resilient enough to allow inner core 26 to be inserted through opening 24 and then to return to its position as shown in FIG. 1 .
- Device 10 is preferably surgically placed proximate a target tissue.
- the surgeon first makes an incision proximate the target tissue.
- the surgeon performs a blunt dissection to a level at or near the target tissue.
- the surgeon uses forceps to hold device 10 with internal surface 14 facing the target tissue and distal end 20 away from the surgeon.
- the surgeon then introduces device 10 into the dissection tunnel, and positions device 10 with internal surface 14 facing the target tissue.
- the surgeon may or may not use sutures to fix device 10 to the underlying tissue, depending on the specific tissue.
- the surgeon sutures the opening and places a strip of antibiotic ointment on the surgical wound.
- body 12 facilitates the unidirectional delivery of a pharmaceutically effective amount of the pharmaceutically active agent from inner core 26 to the target tissue.
- body 12 including the geometry of internal surface 14 , well 22 , opening 24 , and retaining member 28 , facilitate the unidirectional delivery of a pharmaceutically effective amount of the pharmaceutically active agent from inner core 26 to the target tissue.
- the absence of a polymer layer or membrane between inner core 26 and the underlying tissue greatly enhances and simplifies the delivery of an active agent to the target tissue.
- Device 10 can be used to deliver a pharmaceutically effective amount of a pharmaceutically active agent to target tissue for many years, depending on the particular physicochemical properties of the pharmaceutically active agent employed. Important physicochemical properties include hydrophobicity, solubility, dissolution rate, diffusion coefficient, and tissue affinity. After inner core 26 no longer contains active agent, a surgeon may easily remove device 10 . In addition, the “preformed” tunnel facilitates the replacement of an old device 10 with a new device 10 .
- FIGS. 3 through 6 B schematically illustrate an ophthalmic drug delivery device 50 according to a preferred embodiment of the present invention.
- Device 50 may be used in any case where localized delivery of a pharmaceutically active agent to the eye is required.
- Device 50 is particularly useful for localized delivery of active agents to the posterior segment of the eye.
- a preferred use for device 50 is the delivery of pharmaceutically active agents to the retina proximate the macula for treating ARMD, choroidial neovascularization (CNV), retinopathies, retinitis, uveitis, macular edema, and glaucoma.
- CNV choroidial neovascularization
- retinopathies retinitis
- uveitis macular edema
- glaucoma glaucoma
- device 50 may also be utilized for localized delivery of pharmaceutically active agents to body tissue other than the eye, if desired.
- Eye 52 has a cornea 54 , a lens 56 , a sclera 58 , a choroid 60 , a retina 62 , and an optic nerve 64 .
- An anterior segment 66 of eye 52 generally includes the portions of eye 52 anterior of a line 67 .
- a posterior segment 68 of eye 52 generally includes the portions of eye 52 posterior of line 67 .
- Retina 62 is physically attached to choroid 60 in a circumferential manner proximate pars plana 70 .
- Retina 62 has a macula 72 located slightly lateral to its optic disk.
- macula 72 is comprised primarily of retinal cones and is the region of maximum visual acuity in retina 62 .
- a Tenon's capsule or Tenon's membrane 74 is disposed on sclera 58 .
- a conjunctiva 76 covers a short area of the globe of eye 52 posterior to limbus 77 (the bulbar conjunctiva) and folds up (the upper cul-de-sac) or down (the lower cul-de-sac) to cover the inner areas of upper eyelid 78 and lower eyelid 79 , respectively.
- Conjunctiva 76 is disposed on top of Tenon's capsule 74 . As is shown in FIGS.
- device 50 is preferably disposed directly on the outer surface of sclera 58 , below Tenon's capsule 74 for treatment of most posterior segment diseases or conditions.
- device 50 is preferably disposed directly on the outer surface of sclera 58 , below Tenon's capsule 74 , with an inner core of device 50 proximate macula 72 .
- FIGS. 5, 6A , and 6 B schematically illustrate drug delivery device 50 in greater detail.
- Device 50 generally includes a body 80 having a scleral surface 82 and an orbital surface 84 .
- Scleral surface 82 is preferably designed with a radius of curvature that facilitates direct contact with sclera 58 .
- Orbital surface 84 is preferably designed with a radius of curvature that facilitates implantation under Tenon's capsule 74 .
- Body 80 preferably has a curved, generally rectangular three-dimensional geometry with rounded sides 86 and 88 , proximal end 90 , and distal end 92 . As shown best in the side sectional view of FIG.
- orbital surface 84 preferably has tapered surfaces 94 and 96 proximate proximal end 90 and distal end 92 , respectively, that facilitate sub-Tenon implantation of device 50 and enhance the comfort of the patient.
- Body 80 may alternatively have a geometry similar to that of device 10 a shown in FIG. 2 .
- body 80 may have any other geometry that has a curved scleral surface 82 for contact with sclera 58 .
- body 80 may have a generally cylindrical, oval, square, or other polygonal three-dimensional geometry.
- Body 80 includes a well or cavity 102 having an opening 104 to scleral surface 82 .
- An inner core 106 is preferably disposed in well 102 .
- Inner core 106 is preferably a tablet comprising one or more pharmaceutically active agents.
- inner core 106 may comprise a conventional hydrogel having one or more pharmaceutically active agents disposed therein.
- a retaining member 108 is preferably disposed proximate opening 104 . Retaining member 108 prevents inner core 106 from falling out of well 102 .
- retaining member 108 is preferably a continuous rim or lip disposed circumferentially around opening 104 having a diameter slightly less than the diameter of tablet 106 .
- retaining member 108 may comprise one or more members that extend from body 80 into opening 104 .
- inner core 106 may alternatively comprise a suspension, solution, powder, or combination thereof containing one or more pharmaceutically active agents.
- scleral surface 82 is formed without opening 104 , and the suspension, solution, powder, or combination thereof diffuses through the relatively thin portion of scleral surface 82 below inner core 26 .
- device 50 may be formed without well 102 or inner core 106 , and the pharmaceutically active agent(s) in the form of a suspension, solution, powder, or combination thereof may be dispersed throughout body 80 of device 50 . In this embodiment, the pharmaceutically active agent diffuses through body 80 into the target tissue.
- the geometry and dimensions of device 50 maximize communication between the pharmaceutically active agent of inner core 106 and the tissue underlying scleral surface 82 .
- Scleral surface 82 preferably physically contacts the outer surface of sclera 58 .
- inner core 106 may be formed so that surface 106 a physically contacts the outer surface of sclera 58 .
- scleral surface 82 may be disposed proximate the outer surface of sclera 58 .
- device 50 may be disposed in the periocular tissues just above the outer surface of sclera 58 or intra-lamellarly within sclera 58 .
- Body 80 preferably comprises a biocompatible, non-bioerodable material.
- Body 80 more preferably comprises a biocompatible, non-bioerodable polymeric composition.
- Body 80 most preferably is made from a polymeric composition comprising silicone.
- Body 80 is preferably impermeable to the pharmaceutically active agent of inner core 106 .
- the diameter of well 102 may be slightly less than the diameter of inner core 106 . This frictional fit secures inner core 106 within well 102 .
- body 80 may be formed without retaining member 108 , if desired.
- Inner core 106 may comprise any ophthalmically acceptable pharmaceutically active agents suitable for localized delivery.
- Exemplary pharmaceutically active agents include the pharmaceutically active agents listed hereinabove for inner core 26 of device 10 .
- Inner core 106 may also comprise conventional non-active excipients to enhance the stability, solubility, penetrability, or other properties of the active agent.
- inner core 106 is a tablet, it may further comprise conventional excipients necessary for tableting, such as fillers and lubricants. Such tablets may be produced using conventional tableting methods.
- the pharmaceutically active agent is preferably distributed evenly throughout the tablet.
- inner core 106 may comprise a special tablet that bioerodes at a controlled rate, releasing the pharmaceutically active agent. By way of example, such bioerosion may occur through hydrolosis or enzymatic cleavage.
- inner core 106 is a hydrogel, the hydrogel may bioerode at a controlled rate, releasing the pharmaceutically active agent. Alternatively, the hydrogel may be non-bioerodable but allow diffusion of the pharmaceutically active agent.
- Device 50 may be made by conventional polymer processing methods, including, but not limited to, injection molding, extrusion molding, transfer molding, and compression molding. Preferably, device 50 is formed using conventional injection molding techniques as described hereinabove for device 10 .
- Device 50 is preferably surgically placed directly on the outer surface of sclera 58 below Tenon's capsule 74 using a simple surgical technique that is capable of being performed in an outpatient setting.
- the surgeon first performs a peritomy in one of the quadrants of eye 52 .
- the surgeon performs the peritomy in the infra-temporal quadrant, about 3 mm posterior to limbus 77 of eye 52 .
- the surgeon performs a blunt dissection to separate Tenon's capsule 74 from sclera 58 , forming an antero-posterior tunnel.
- the surgeon uses forceps to hold device 50 with scleral surface 82 facing sclera 58 and distal end 92 away from the surgeon.
- the surgeon then introduces device 50 into the tunnel in a generally circular motion to position inner core 106 of device 50 generally above the desired portion of retina 62 .
- the surgeon then closes the peritomy by suturing Tenon's capsule 74 and conjunctiva 76 to sclera 58 . After closing, the surgeon places a strip of antibiotic ointment on the surgical wound.
- the surgeon may suture proximal end 90 of device 50 to sclera 58 to hold device 50 in the desired location before closure of the tunnel.
- the surgeon utilizes the above-described technique to position inner core 106 of device 50 in one of two preferred locations in the infra-temporal quadrant of eye 52 .
- One preferred location is directly on the outer surface of sclera 58 , below Tenon's capsule 74 , with inner core 106 positioned proximate to, but not directly above, macula 72 .
- a surgeon may position inner core 106 of device 50 at this location by moving distal end 92 of device 50 below the inferior oblique muscle in a direction generally parallel to the lateral rectus muscle.
- a second preferred location is directly on the outer surface of sclera 58 , below Tenon's capsule 74 , with inner core 106 positioned directly above macula 72 .
- a surgeon may position inner core 106 of device 50 at this location by moving distal end 92 of device 50 toward macula 72 along a path generally between the lateral and inferior rectus muscles and below the inferior oblique muscle.
- the pharmaceutically active agent of inner core 106 is preferably one of the angiostatic steroids disclosed in U.S. Pat. Nos. 5,679,666 and 5,770,592.
- body 80 of device 50 including the geometry of scleral surface 82 , well 102 , opening 104 , and retaining member 108 , facilitate the unidirectional delivery of a pharmaceutically effective amount of the pharmaceutically active agent from inner core 106 through sclera 58 , choroid 60 , and into retina 62 .
- the absence of a polymer layer or membrane between inner core 106 and sclera 58 greatly enhances and simplifies the delivery of an active agent to retina 62 .
- device 50 can be used to deliver a pharmaceutically effective amount of a pharmaceutically active agent to retina 62 for many years, depending on the particular physicochemical properties of the pharmaceutically active agent employed.
- Important physicochemical properties include hydrophobicity, solubility, dissolution rate, diffusion coefficient, and tissue affinity.
- a device 50 was surgically implanted on the outer surface of the sclera, below the Tenon's capsule, generally along the inferior border of the lateral rectus muscle of the right eye of twenty (20) New Zealand White rabbits using a procedure similar to that described hereinabove for implantation of device 50 on sclera 58 of eye 52 .
- Device 50 was constructed as shown in FIGS. 5 through 6 B, with the following dimensions.
- Body 80 had a length 110 of about 15 mm, a width 112 of about 7.0 mm, and a maximum thickness 114 of about 1.8 mm.
- Retaining member 108 had a thickness 116 of about 0.15 mm.
- Scleral surface 82 had a radius of curvature of about 8.5 mm and an arc length of about 18 mm.
- Inner core 106 was a cylindrical tablet with a diameter of about 5.0 mm and a thickness of about 1.5 mm. Opening 104 had a diameter of about 3.8 mm. Well 102 had a diameter of about 4.4 mm.
- the pharmaceutically active agent used in tablet 106 was 4,9(11)-Pregnadien-17 ⁇ ,21-diol-3,20-dione, an angiostatic steroid sold by Steraloids, Inc. of Wilton, N.H., and which is more fully disclosed in U.S. Pat. Nos. 5,770,592 and 5,679,666.
- the formulation of tablet 106 consisted of 99.75 weight percent 4,9(11)-Pregnadien-17 ⁇ ,21-diol-3,20-dione, and 0.25 weight percent magnesium stearate.
- a 10 mm diameter circular zone of retinal tissue was harvested (the “target site”).
- a 10 mm diameter circular zone of retinal tissue was also harvested from a second site located remote from the target site and on the other side of the optic nerve.
- a 10 mm diameter circular zone of retinal tissue was harvested from a third site located between the second site and the target site.
- FIG. 7 shows the mean concentration of 4,9(11)-Pregnadien-17 ⁇ ,21-diol-3,20-dione in the retina and the choroid at the target site as a function of time.
- the “error bars” surrounding each data point represent standard deviation.
- device 50 delivered a pharmaceutically effective and generally constant amount of 4,9(11)-Pregnadien-17 ⁇ ,21-diol-3,20-dione to the retina and the choroid at the target site for a time period of up to twelve weeks.
- the levels of 4,9(11)-Pregnadien-17 ⁇ ,21-diol-3,20-dione in the retina and the choroid at the second and third sites were at or near zero. Therefore, device 50 also delivered a localized dose of angiostatic steroid to the retina and the choroid at the target site.
- the present invention provides improved devices and methods for safe, effective, rate-controlled, localized delivery of a variety of pharmaceutically active agents to any body tissue.
- the surgical procedure for implanting such devices is safe, simple, quick, and capable of being performed in an outpatient setting.
- Such devices are easy and economical to manufacture.
- such devices are useful in clinical studies to deliver various agents that create a specific physical condition in a patient or animal subject.
- such devices are especially useful for localized delivery of pharmaceutically active agents to the posterior segment of the eye to combat ARMD, CNV, retinopathies, retinitis, uveitis, macular edema, and glaucoma.
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Prostheses (AREA)
Abstract
Drug delivery devices, and methods of delivering pharmaceutically active agents to a target tissue within a body using such devices, are disclosed. One drug delivery device includes a body having an internal surface for placement proximate a target tissue and a well having an opening to the internal surface. An inner core comprising a pharmaceutically active agent is disposed in the well.
Description
- This application is a continuation of U.S. application Ser. No. 10/186,960, filed Jul. 1, 2002, which is a continuation of U.S. application Ser. No. 09/660,000, filed Sep. 12, 2000, now U.S. Pat. No. 6,413,540, which claims priority from U.S. Provisional Application No. 60/160,673, filed Oct. 21, 1999.
- The present invention generally pertains to biocompatible implants for localized delivery of pharmaceutically active agents to body tissue. More particularly, but not by way of limitation, the present invention pertains to biocompatible implants for localized delivery of pharmaceutically active agents to the posterior segment of the eye.
- Several diseases and conditions of the posterior segment of the eye threaten vision. Age related macular degeneration (ARMD), choroidal neovascularization (CNV), retinopathies (i.e. diabetic retinopathy, vitreoretinopathy), retinitis (i.e. cytomegalovirus (CMV) retinitis), uveitis, macular edema, and glaucoma are several examples.
- Age related macular degeneration (ARMD) is the leading cause of blindness in the elderly. ARMD attacks the center of vision and blurs it, making reading, driving, and other detailed tasks difficult or impossible. About 200,000 new cases of ARMD occur each year in the United States alone. Current estimates reveal that approximately forty percent of the population over age 75, and approximately twenty percent of the population over
age 60, suffer from some degree of macular degeneration. “Wet” ARMD is the type of ARMD that most often causes blindness. In wet ARMD, newly formed choroidal blood vessels (choroidal neovascularization (CNV)) leak fluid and cause progressive damage to the retina. - In the particular case of CNV in ARMD, two main methods of treatment are currently being developed, (a) photocoagulation and (b) the use of angiogenesis inhibitors. However, photocoagulation can be harmful to the retina and is impractical when the CNV is near the fovea. Furthermore, photocoagulation often results in recurrent CNV over time. Oral or parenteral (non-ocular) administration of anti-angiogenic compounds is also being tested as a systemic treatment for ARMD. However, due to drug-specific metabolic restrictions, systemic administration usually provides sub-therapeutic drug levels to the eye. Therefore, to achieve effective intraocular drug concentrations, either an unacceptably high dose or repetitive conventional doses are required. Periocular injections of these compounds often result in the drug being quickly washed out and depleted from the eye, via periocular vasculature and soft tissue, into the general circulation. Repetitive intraocular injections may result in severe, often blinding, complications such as retinal detachment and endophthalmitis.
- In order to prevent complications related to the above-described treatments and to provide better ocular treatment, researchers have suggested various implants aimed at localized delivery of anti-angiogenic compounds to the eye. U.S. Pat. No. 5,824,072 to Wong discloses a non-biodegradable polymeric implant with a pharmaceutically active agent disposed therein. The pharmaceutically active agent diffuses through the polymer body of the implant into the target tissue. The pharmaceutically active agent may include drugs for the treatment of macular degeneration and diabetic retinopathy. The implant is placed substantially within the tear fluid upon the outer surface of the eye over an avascular region, and may be anchored in the conjunctiva or sclera; episclerally or intrasclerally over an avascular region; substantially within the suprachoroidial space over an avascular region such as the pars plana or a surgically induced avascular region; or in direct communication with the vitreous.
- U.S. Pat. No. 5,476,511 to Gwon et al. discloses a polymer implant for placement under the conjunctiva of the eye. The implant may be used to deliver neovascular inhibitors for the treatment of ARMD and drugs for the treatment of retinopathies, retinitis, and CMV retinitis. The pharmaceutically active agent diffuses through the polymer body of the implant.
- U.S. Pat. No. 5,773,019 to Ashton et al. discloses a non-bioerodable polymer implant for delivery of certain drugs including angiostatic steroids and drugs such as cyclosporine for the treatment of uveitis. Once again, the pharmaceutically active agent diffuses through the polymer body of the implant.
- All of the above-described implants require careful design and manufacture to permit controlled diffusion of the pharmaceutically active agent through a polymer body (matrix devices) or polymer membrane (reservoir devices) to the desired site of therapy. Drug release from these devices depends on the porosity and diffusion characteristics of the matrix or membrane, respectively. These parameters must be tailored for each drug moiety to be used with these devices. Consequently, these requirements generally increase the complexity and cost of such implants.
- U.S. Pat. No. 5,824,073 to Peyman discloses an indentor for positioning in the eye. The indentor has a raised portion that is used to indent or apply pressure to the sclera over the macular area of the eye. This patent discloses that such pressure decreases choroidal congestion and blood flow through the subretinal neovascular membrane, which, in turn, decreases bleeding and subretinal fluid accumulation.
- Therefore, a need exists in the biocompatible implant field for a surgically implantable drug delivery device capable of safe, effective, rate-controlled, localized delivery of a wide variety of pharmaceutically active agents to any body tissue. The surgical procedure for implanting such a device should be safe, simple, quick, and capable of being performed in an outpatient setting. Ideally, such a device should be easy and economical to manufacture. Furthermore, because of its versatility and capability to deliver a wide variety of pharmaceutically active agents, such an implant should be capable of use in clinical studies to deliver various agents that create a specific physical condition in a patient or animal subject. In the particular field of ophthalmic drug delivery, such an implantable drug delivery device is especially needed for localized delivery of pharmaceutically active agents to the posterior segment of the eye to combat ARMD, CNV, retinopathies, retinitis, uveitis, macular edema, and glaucoma.
- One aspect of the present invention comprises a drug delivery device including a body having an internal surface for placement proximate a target tissue and a well having an opening to the internal surface. An inner core comprising a pharmaceutically active agent is disposed in the well.
- In another aspect, the present invention comprises a method of delivering a pharmaceutically active agent to a target tissue within a body. A drug delivery device is provided. The drug delivery device includes a body having an internal surface and a well having an opening to the internal surface, and an inner core disposed in the well comprising a pharmaceutically active agent. The device is disposed within the body so that the pharmaceutically active agent is in communication with the target tissue through the opening.
- In a further aspect, the present invention comprises an ophthalmic drug delivery device including a body having a scleral surface for placement proximate a sclera and a well or cavity having an opening to the scleral surface. An inner core comprising a pharmaceutically active agent is disposed in the well.
- In a further aspect, the present invention comprises a method of delivering a pharmaceutically active agent to an eye having a sclera. A drug delivery device is provided. The drug delivery device includes a body having a scleral surface and a well having an opening to the scleral surface, and an inner core disposed in the well comprising a pharmaceutically active agent. The device is disposed within the eye so that the pharmaceutically active agent is in communication with the sclera through the opening.
- In a further aspect, the present invention comprises a method of delivering a pharmaceutically active agent to an eye having a sclera, a Tenon's capsule, and a macula. A drug delivery device comprising a body having a pharmaceutically active agent disposed therein is provided. The device is disposed on an outer surface of the sclera, below the Tenon's capsule, and proximate the macula.
- For a more complete understanding of the present invention, and for further objects and advantages thereof, reference is made to the following description taken in conjunction with the accompanying drawings in which:
-
FIG. 1 is a side sectional view of a drug delivery device according to a preferred embodiment of the present invention; -
FIG. 2 is a side sectional view of a second drug delivery device according to a preferred embodiment of the present invention; -
FIG. 3 is a side sectional view schematically illustrating the human eye; -
FIG. 4 is detailed cross-sectional view of the eye ofFIG. 3 along line 4-4; -
FIG. 5 is a perspective view of an ophthalmic drug delivery device according to a preferred embodiment of the present invention; -
FIG. 6A is a side sectional view of the ophthalmic drug delivery device ofFIG. 5 ; -
FIG. 6B is an enlarged cross-sectional view of the ophthalmic drug delivery device ofFIG. 6A taken alongline 6B-6B; and -
FIG. 7 is a graphical illustration of the results of a pharmacokinetic study with New Zealand White rabbits implanted with the ophthalmic drug delivery device ofFIGS. 5 through 6 B showing the mean concentration of a pharmaceutically active agent at a target site in the retina and choroid of the rabbits as a function of time. - The preferred embodiments of the present invention and their advantages are best understood by referring to
FIGS. 1 through 7 of the drawings, like numerals being used for like and corresponding parts of the various drawings. -
FIG. 1 schematically illustrates adrug delivery device 10 according to a preferred embodiment of the present invention.Device 10 may be used in any case where localized delivery of a pharmaceutically active agent to body tissue is required. By way of example,device 10 may be used to treat a medical disorder of the eye, ear, nose, throat, skin, subcutaneous tissue, or bone.Device 10 may be used in humans or animals. -
Device 10 generally includes abody 12 having aninternal surface 14 and anexternal surface 16. As shown inFIG. 1 ,body 12 preferably has a generally rectangular three-dimensional geometry with aproximal end 18 and adistal end 20.Body 12 may have any other geometry that has aninternal surface 14 for placement proximate a target tissue in the body of a patient. By way of example,body 12 may have a cylindrical, an oval, a square, or other polygonal three-dimensional geometry. -
Body 12 includes a well orcavity 22 having anopening 24 tointernal surface 14. Aninner core 26 is preferably disposed inwell 22.Inner core 26 is preferably a tablet comprising one or more pharmaceutically active agents. Alternatively,inner core 26 may comprise a conventional hydrogel having one or more pharmaceutically active agents disposed therein. A retainingmember 28 is preferably disposedproximate opening 24. Retainingmember 28 preventsinner core 26 from falling out of well 22. Wheninner core 26 is a cylindrical tablet, retainingmember 28 is preferably a continuous rim or lip disposed circumferentially around opening 24 having a diameter slightly less than the diameter oftablet 26. Alternatively, retainingmember 26 may comprise one or more members that extend frombody 12 intoopening 24. Although not shown inFIG. 1 ,inner core 26 may alternatively comprise a suspension, solution, powder, or combination thereof containing one or more pharmaceutically active agents. In this embodiment,internal surface 14 is formed without opening 24, and the suspension, solution, powder, or combination thereof diffuses through the relatively thin portion ofinternal surface 14 belowinner core 26. Still further in the alternative,device 10 may be formed without well 22 orinner core 26, and the pharmaceutically active agent(s) in the form of a suspension, solution, powder, or combination thereof may be dispersed throughoutbody 12 ofdevice 10. In this embodiment, the pharmaceutically active agent diffuses throughbody 12 into the target tissue. - The geometry of
device 10 maximizes communication between the pharmaceutically active agent ofinner core 26 and the tissue underlyinginternal surface 14.Internal surface 14 preferably physically contacts the target tissue. By way of example, if the target tissue has a generally flat surface,device 10 would be appropriate for the delivery of a pharmaceutically active agent. As another example, if the target tissue has a generally convex surface, adevice 10 a shown inFIG. 2 having a generally concaveinternal surface 14 a designed to mate with such a target surface may be utilized.Corners 30 ofproximal end 18 a, andcorners 32 ofdistal end 20 a, may be slanted and/or rounded off to facilitate surgical placement ofdevice 10 a and to maximize comfort to the patient. Retainingmember 28 is preferably designed with a minimum thickness necessary to retaininner core 26 so as to dispose asurface 26 a ofinner core 26 in close proximity to the target tissue. Although not shown inFIG. 1 or 2,inner core 26 may be formed so thatsurface 26 a physically contacts the target tissue. - Alternatively,
device internal surface internal surface inner core 26 communicates with the target tissue throughopening 24 and this intermediate tissue. - Referring again to
FIG. 1 ,body 12 preferably comprises a biocompatible, non-bioerodable material.Body 12 more preferably comprises a biocompatible, non-bioerodable polymeric composition. Said polymeric composition may be a homopolymer, a copolymer, straight, branched, cross-linked, or a blend. Examples of polymers suitable for use in said polymeric composition include silicone, polyvinyl alcohol, ethylene vinyl acetate, polylactic acid, nylon, polypropylene, polycarbonate, cellulose, cellulose acetate, polyglycolic acid, polylactic-glycolic acid, cellulose esters, polyethersulfone, acrylics, their derivatives, and combinations thereof. Examples of suitable soft acrylics are more fully disclosed in U.S. Pat. No. 5,403,901, which is incorporated herein in its entirety by reference. Said polymeric composition most preferably comprises silicone. Of course, said polymeric composition may also comprise other conventional materials that affect its physical properties, including, but not limited to, porosity, tortuosity, permeability, rigidity, hardness, and smoothness. Exemplary materials affecting certain ones of these physical properties include conventional plasticizers, fillers, and lubricants. Said polymeric composition may comprise other conventional materials that affect its chemical properties, including, but not limited to, toxicity, hydrophobicity, andbody 12—inner core 26 interaction.Body 12 is preferably impermeable to the pharmaceutically active agent ofinner core 26. Whenbody 12 is made from a generally elastic polymeric composition, the diameter of well 22 may be slightly less than the diameter ofinner core 26. This frictional fit securesinner core 26 within well 22. In this embodiment,body 12 may be formed without retainingmember 28, if desired. -
Inner core 26 may comprise any pharmaceutically active agents suitable for localized delivery to a target tissue. Examples of pharmaceutically active agents suitable forinner core 26 are anti-infectives, including, without limitation, antibiotics, antivirals, and antifungals; antiallergenic agents and mast cell stabilizers; steroidal and non-steroidal anti-inflammatory agents; combinations of anti-infective and anti-inflammatory agents; decongestants; anti-glaucoma agents, including, without limitation, adrenergics, β-adrenergic blocking agents, α-adrenergic agonists, parasypathomimetic agents, cholinesterase inhibitors, carbonic anhydrase inhibitors, and prostaglandins; combinations of anti-glaucoma agents; antioxidants; nutritional supplements; drugs for the treatment of cystoid macular edema including, without limitation, non-steroidal anti-inflammatory agents; drugs for the treatment of ARMD, including, without limitation, angiogenesis inhibitors and nutritional supplements; drugs for the treatment of herpetic infections and CMV ocular infections; drugs for the treatment of proliferative vitreoretinopathy including, without limitation, antimetabolites and fibrinolytics; wound modulating agents, including, without limitation, growth factors; antimetabolites; neuroprotective drugs, including, without limitation, eliprodil; and angiostatic steroids for the treatment of diseases or conditions of the posterior segment of the eye, including, without limitation, ARMD, CNV, retinopathies, retinitis, uveitis, macular edema, and glaucoma. Such angiostatic steroids are more fully disclosed in U.S. Pat. Nos. 5,679,666 and 5,770,592, which are incorporated herein in their entirety by reference. Preferred ones of such angiostatic steroids include 4,9(11)-Pregnadien-17α,21-diol-3,20-dione and 4,9(11)-Pregnadien-17α,21-diol-3,20-dione-21-acetate.Inner core 26 may also comprise conventional non-active excipients to enhance the stability, solubility, penetrability, or other properties of the active agent or the drug core. - If
inner core 26 is a tablet, it may further comprise conventional excipients necessary for tableting, such as fillers and lubricants. Such tablets may be produced using conventional tableting methods. The pharmaceutically active agent is preferably distributed evenly throughout the tablet. In addition to conventional tablets,inner core 26 may comprise a special tablet that bioerodes at a controlled rate, releasing the pharmaceutically active agent. By way of example, such bioerosion may occur through hydrolosis or enzymatic cleavage. Ifinner core 26 is a hydrogel, the hydrogel may bioerode at a controlled rate, releasing the pharmaceutically active agent. Alternatively, the hydrogel may be non-bioerodable but allow diffusion of the pharmaceutically active agent. -
Device 10 may be made by conventional polymer processing methods, including, but not limited to, injection molding, extrusion molding, transfer molding, and compression molding. Preferably,device 10 is formed using conventional injection molding techniques.Inner core 26 is preferably disposed in well 22 after the formation ofbody 12 ofdevice 10. Retainingmember 28 is preferably resilient enough to allowinner core 26 to be inserted throughopening 24 and then to return to its position as shown inFIG. 1 . -
Device 10 is preferably surgically placed proximate a target tissue. The surgeon first makes an incision proximate the target tissue. Next, the surgeon performs a blunt dissection to a level at or near the target tissue. Once the target tissue is located, the surgeon uses forceps to holddevice 10 withinternal surface 14 facing the target tissue anddistal end 20 away from the surgeon. The surgeon then introducesdevice 10 into the dissection tunnel, andpositions device 10 withinternal surface 14 facing the target tissue. Once in place, the surgeon may or may not use sutures to fixdevice 10 to the underlying tissue, depending on the specific tissue. After placement, the surgeon sutures the opening and places a strip of antibiotic ointment on the surgical wound. - The physical shape of
body 12, including the geometry ofinternal surface 14, well 22, opening 24, and retainingmember 28, facilitate the unidirectional delivery of a pharmaceutically effective amount of the pharmaceutically active agent frominner core 26 to the target tissue. In particular, the absence of a polymer layer or membrane betweeninner core 26 and the underlying tissue greatly enhances and simplifies the delivery of an active agent to the target tissue. -
Device 10 can be used to deliver a pharmaceutically effective amount of a pharmaceutically active agent to target tissue for many years, depending on the particular physicochemical properties of the pharmaceutically active agent employed. Important physicochemical properties include hydrophobicity, solubility, dissolution rate, diffusion coefficient, and tissue affinity. Afterinner core 26 no longer contains active agent, a surgeon may easily removedevice 10. In addition, the “preformed” tunnel facilitates the replacement of anold device 10 with anew device 10. -
FIGS. 3 through 6 B schematically illustrate an ophthalmicdrug delivery device 50 according to a preferred embodiment of the present invention.Device 50 may be used in any case where localized delivery of a pharmaceutically active agent to the eye is required.Device 50 is particularly useful for localized delivery of active agents to the posterior segment of the eye. A preferred use fordevice 50 is the delivery of pharmaceutically active agents to the retina proximate the macula for treating ARMD, choroidial neovascularization (CNV), retinopathies, retinitis, uveitis, macular edema, and glaucoma. Of course,device 50 may also be utilized for localized delivery of pharmaceutically active agents to body tissue other than the eye, if desired. - Referring first to
FIG. 3 , ahuman eye 52 is schematically illustrated.Eye 52 has acornea 54, alens 56, asclera 58, achoroid 60, aretina 62, and anoptic nerve 64. Ananterior segment 66 ofeye 52 generally includes the portions ofeye 52 anterior of aline 67. Aposterior segment 68 ofeye 52 generally includes the portions ofeye 52 posterior ofline 67.Retina 62 is physically attached tochoroid 60 in a circumferential manner proximate pars plana 70.Retina 62 has a macula 72 located slightly lateral to its optic disk. As is well known in the ophthahnic art,macula 72 is comprised primarily of retinal cones and is the region of maximum visual acuity inretina 62. A Tenon's capsule or Tenon'smembrane 74 is disposed onsclera 58. Aconjunctiva 76 covers a short area of the globe ofeye 52 posterior to limbus 77 (the bulbar conjunctiva) and folds up (the upper cul-de-sac) or down (the lower cul-de-sac) to cover the inner areas ofupper eyelid 78 andlower eyelid 79, respectively.Conjunctiva 76 is disposed on top of Tenon'scapsule 74. As is shown inFIGS. 3 and 4 , and as is described in greater detail hereinbelow,device 50 is preferably disposed directly on the outer surface ofsclera 58, below Tenon'scapsule 74 for treatment of most posterior segment diseases or conditions. In addition, for treatment of ARMD in humans,device 50 is preferably disposed directly on the outer surface ofsclera 58, below Tenon'scapsule 74, with an inner core ofdevice 50proximate macula 72. -
FIGS. 5, 6A , and 6B schematically illustratedrug delivery device 50 in greater detail.Device 50 generally includes abody 80 having ascleral surface 82 and anorbital surface 84.Scleral surface 82 is preferably designed with a radius of curvature that facilitates direct contact withsclera 58.Orbital surface 84 is preferably designed with a radius of curvature that facilitates implantation under Tenon'scapsule 74.Body 80 preferably has a curved, generally rectangular three-dimensional geometry withrounded sides proximal end 90, anddistal end 92. As shown best in the side sectional view ofFIG. 6A ,orbital surface 84 preferably has taperedsurfaces proximal end 90 anddistal end 92, respectively, that facilitate sub-Tenon implantation ofdevice 50 and enhance the comfort of the patient.Body 80 may alternatively have a geometry similar to that ofdevice 10 a shown inFIG. 2 . In addition,body 80 may have any other geometry that has a curvedscleral surface 82 for contact withsclera 58. By way of example,body 80 may have a generally cylindrical, oval, square, or other polygonal three-dimensional geometry. -
Body 80 includes a well orcavity 102 having anopening 104 toscleral surface 82. Aninner core 106 is preferably disposed inwell 102.Inner core 106 is preferably a tablet comprising one or more pharmaceutically active agents. Alternatively,inner core 106 may comprise a conventional hydrogel having one or more pharmaceutically active agents disposed therein. A retainingmember 108 is preferably disposedproximate opening 104. Retainingmember 108 preventsinner core 106 from falling out ofwell 102. Wheninner core 106 is a cylindrical tablet, retainingmember 108 is preferably a continuous rim or lip disposed circumferentially around opening 104 having a diameter slightly less than the diameter oftablet 106. Alternatively, retainingmember 108 may comprise one or more members that extend frombody 80 intoopening 104. Although not shown inFIG. 6A ,inner core 106 may alternatively comprise a suspension, solution, powder, or combination thereof containing one or more pharmaceutically active agents. In this embodiment,scleral surface 82 is formed without opening 104, and the suspension, solution, powder, or combination thereof diffuses through the relatively thin portion ofscleral surface 82 belowinner core 26. Still further in the alternative,device 50 may be formed without well 102 orinner core 106, and the pharmaceutically active agent(s) in the form of a suspension, solution, powder, or combination thereof may be dispersed throughoutbody 80 ofdevice 50. In this embodiment, the pharmaceutically active agent diffuses throughbody 80 into the target tissue. - The geometry and dimensions of
device 50 maximize communication between the pharmaceutically active agent ofinner core 106 and the tissue underlyingscleral surface 82.Scleral surface 82 preferably physically contacts the outer surface ofsclera 58. Although not shown inFIG. 6A or 6B,inner core 106 may be formed so thatsurface 106 a physically contacts the outer surface ofsclera 58. Alternatively,scleral surface 82 may be disposed proximate the outer surface ofsclera 58. By way of example,device 50 may be disposed in the periocular tissues just above the outer surface ofsclera 58 or intra-lamellarly withinsclera 58. -
Body 80 preferably comprises a biocompatible, non-bioerodable material.Body 80 more preferably comprises a biocompatible, non-bioerodable polymeric composition. The polymericcomposition comprising body 80, and the polymers suitable for use in the polymeric compositions ofbody 80, may be any of the compositions and polymers described hereinabove forbody 12 ofdevice 10.Body 80 most preferably is made from a polymeric composition comprising silicone.Body 80 is preferably impermeable to the pharmaceutically active agent ofinner core 106. Whenbody 80 is made from a generally elastic polymeric composition, the diameter of well 102 may be slightly less than the diameter ofinner core 106. This frictional fit securesinner core 106 within well 102. In this embodiment,body 80 may be formed without retainingmember 108, if desired. -
Inner core 106 may comprise any ophthalmically acceptable pharmaceutically active agents suitable for localized delivery. Exemplary pharmaceutically active agents include the pharmaceutically active agents listed hereinabove forinner core 26 ofdevice 10.Inner core 106 may also comprise conventional non-active excipients to enhance the stability, solubility, penetrability, or other properties of the active agent. - If
inner core 106 is a tablet, it may further comprise conventional excipients necessary for tableting, such as fillers and lubricants. Such tablets may be produced using conventional tableting methods. The pharmaceutically active agent is preferably distributed evenly throughout the tablet. In addition to conventional tablets,inner core 106 may comprise a special tablet that bioerodes at a controlled rate, releasing the pharmaceutically active agent. By way of example, such bioerosion may occur through hydrolosis or enzymatic cleavage. Ifinner core 106 is a hydrogel, the hydrogel may bioerode at a controlled rate, releasing the pharmaceutically active agent. Alternatively, the hydrogel may be non-bioerodable but allow diffusion of the pharmaceutically active agent. -
Device 50 may be made by conventional polymer processing methods, including, but not limited to, injection molding, extrusion molding, transfer molding, and compression molding. Preferably,device 50 is formed using conventional injection molding techniques as described hereinabove fordevice 10. -
Device 50 is preferably surgically placed directly on the outer surface ofsclera 58 below Tenon'scapsule 74 using a simple surgical technique that is capable of being performed in an outpatient setting. The surgeon first performs a peritomy in one of the quadrants ofeye 52. Preferably, the surgeon performs the peritomy in the infra-temporal quadrant, about 3 mm posterior to limbus 77 ofeye 52. Once this incision is made, the surgeon performs a blunt dissection to separate Tenon'scapsule 74 fromsclera 58, forming an antero-posterior tunnel. Once the tunnel is formed, the surgeon uses forceps to holddevice 50 withscleral surface 82 facingsclera 58 anddistal end 92 away from the surgeon. The surgeon then introducesdevice 50 into the tunnel in a generally circular motion to positioninner core 106 ofdevice 50 generally above the desired portion ofretina 62. The surgeon then closes the peritomy by suturing Tenon'scapsule 74 andconjunctiva 76 tosclera 58. After closing, the surgeon places a strip of antibiotic ointment on the surgical wound. Alternatively, the surgeon may sutureproximal end 90 ofdevice 50 to sclera 58 to holddevice 50 in the desired location before closure of the tunnel. - In the case of ARMD in the human eye, the surgeon utilizes the above-described technique to position
inner core 106 ofdevice 50 in one of two preferred locations in the infra-temporal quadrant ofeye 52. One preferred location is directly on the outer surface ofsclera 58, below Tenon'scapsule 74, withinner core 106 positioned proximate to, but not directly above,macula 72. A surgeon may positioninner core 106 ofdevice 50 at this location by movingdistal end 92 ofdevice 50 below the inferior oblique muscle in a direction generally parallel to the lateral rectus muscle. A second preferred location is directly on the outer surface ofsclera 58, below Tenon'scapsule 74, withinner core 106 positioned directly abovemacula 72. A surgeon may positioninner core 106 ofdevice 50 at this location by movingdistal end 92 ofdevice 50 towardmacula 72 along a path generally between the lateral and inferior rectus muscles and below the inferior oblique muscle. For ARMD, the pharmaceutically active agent ofinner core 106 is preferably one of the angiostatic steroids disclosed in U.S. Pat. Nos. 5,679,666 and 5,770,592. - The physical shape of
body 80 ofdevice 50, including the geometry ofscleral surface 82, well 102, opening 104, and retainingmember 108, facilitate the unidirectional delivery of a pharmaceutically effective amount of the pharmaceutically active agent frominner core 106 throughsclera 58,choroid 60, and intoretina 62. In particular, the absence of a polymer layer or membrane betweeninner core 106 andsclera 58 greatly enhances and simplifies the delivery of an active agent toretina 62. - It is believed that
device 50 can be used to deliver a pharmaceutically effective amount of a pharmaceutically active agent toretina 62 for many years, depending on the particular physicochemical properties of the pharmaceutically active agent employed. Important physicochemical properties include hydrophobicity, solubility, dissolution rate, diffusion coefficient, and tissue affinity. Afterinner core 106 no longer contains active agent, a surgeon may easily removedevice 50. In addition, the “pre-formed” tunnel facilitates the replacement of anold device 50 with anew device 50. - The following example illustrates effective drug delivery to a rabbit retina using a preferred embodiment and surgical technique of the present invention, but are in no way limiting.
- A
device 50 was surgically implanted on the outer surface of the sclera, below the Tenon's capsule, generally along the inferior border of the lateral rectus muscle of the right eye of twenty (20) New Zealand White rabbits using a procedure similar to that described hereinabove for implantation ofdevice 50 onsclera 58 ofeye 52.Device 50 was constructed as shown inFIGS. 5 through 6 B, with the following dimensions.Body 80 had alength 110 of about 15 mm, awidth 112 of about 7.0 mm, and amaximum thickness 114 of about 1.8 mm. Retainingmember 108 had athickness 116 of about 0.15 mm.Scleral surface 82 had a radius of curvature of about 8.5 mm and an arc length of about 18 mm.Inner core 106 was a cylindrical tablet with a diameter of about 5.0 mm and a thickness of about 1.5 mm. Opening 104 had a diameter of about 3.8 mm. Well 102 had a diameter of about 4.4 mm. The pharmaceutically active agent used intablet 106 was 4,9(11)-Pregnadien-17α,21-diol-3,20-dione, an angiostatic steroid sold by Steraloids, Inc. of Wilton, N.H., and which is more fully disclosed in U.S. Pat. Nos. 5,770,592 and 5,679,666. The formulation oftablet 106 consisted of 99.75weight percent 4,9(11)-Pregnadien-17α,21-diol-3,20-dione, and 0.25 weight percent magnesium stearate. - At one week after implantation, 4 rabbits were euthanized and their right eyes were enucleated. The
device 50 was removed from the eyes, and the location oftablet 106 was marked on their sclerae. Following the removal of the anterior segment and the vitreous of each eye and inversion of the thus formed eye-cup, a 10 mm diameter circular zone of retinal tissue, concentric with and below the location oftablet 106 on the sclera, was harvested (the “target site”). A 10 mm diameter circular zone of retinal tissue was also harvested from a second site located remote from the target site and on the other side of the optic nerve. In addition, a 10 mm diameter circular zone of retinal tissue was harvested from a third site located between the second site and the target site. Similar 10 mm diameter circular zones of choroidal tissue were also harvested at the target site, second site, and third site. All these tissues were separately homogenized, and the concentration of angiostatic steroid in each of these tissues was determined via an ocular pharmacokinetic study using high performance liquid chromatography and mass spectrometry analysis (LC-MS/MS). This procedure was repeated at 3, 6, 9, and 12 weeks after implantation. -
FIG. 7 shows the mean concentration of 4,9(11)-Pregnadien-17α,21-diol-3,20-dione in the retina and the choroid at the target site as a function of time. The “error bars” surrounding each data point represent standard deviation. As shown inFIG. 7 ,device 50 delivered a pharmaceutically effective and generally constant amount of 4,9(11)-Pregnadien-17α,21-diol-3,20-dione to the retina and the choroid at the target site for a time period of up to twelve weeks. In contrast, the levels of 4,9(11)-Pregnadien-17α,21-diol-3,20-dione in the retina and the choroid at the second and third sites were at or near zero. Therefore,device 50 also delivered a localized dose of angiostatic steroid to the retina and the choroid at the target site. - From the above, it may be appreciated that the present invention provides improved devices and methods for safe, effective, rate-controlled, localized delivery of a variety of pharmaceutically active agents to any body tissue. The surgical procedure for implanting such devices is safe, simple, quick, and capable of being performed in an outpatient setting. Such devices are easy and economical to manufacture. Furthermore, because of their capability to deliver a wide variety of pharmaceutically active agents, such devices are useful in clinical studies to deliver various agents that create a specific physical condition in a patient or animal subject. In the particular field of ophthalmic drug delivery, such devices are especially useful for localized delivery of pharmaceutically active agents to the posterior segment of the eye to combat ARMD, CNV, retinopathies, retinitis, uveitis, macular edema, and glaucoma.
- It is believed that the operation and construction of the present invention will be apparent from the foregoing description. While the apparatus and methods shown or described above have been characterized as being preferred, various changes and modifications may be made therein without departing from the spirit and scope of the invention as defined in the following claims.
Claims (13)
1. An ophthalmic drug delivery device, comprising:
a body having:
a scleral surface having a radius of curvature that facilitates contact with a sclera of a human eye;
a well having an opening to said scleral surface; and
a geometry that facilitates disposing said device on an outer surface of said sclera, below a Tenon's capsule of said eye, and in a posterior segment of said eye; and
an inner core disposed in said well and comprising a pharmaceutically active agent.
2. The ophthalmic drug delivery device of claim 1 , wherein said body has a geometry that facilitates disposing said device on said outer surface of said sclera, below said Tenon's capsule, and in said posterior segment so that said inner core is disposed proximate a macula of said eye.
3. The ophthalmic drug delivery device of claim 2 , wherein said body has a geometry that facilitates disposing said device on said outer surface of said sclera, below said Tenon's capsule, and in said posterior segment so that said inner core is disposed generally above said macula.
4. The ophthalmic drug delivery device of claim 1 , wherein said inner core is a tablet.
5. The ophthalmic drug delivery device of claim 4 , wherein at least a portion of said body is made from a generally elastic material so that said generally elastic material, a geometry of said well, and a geometry of said tablet frictionally secure said tablet within said well.
6. The ophthalmic drug delivery device of claim 4 , wherein said tablet is formulated to bioerode and release said pharmaceutically active agent at a controlled rate.
7. The ophthalmic drug delivery device of claim 1 , wherein said inner core is a hydrogel.
8. The ophthalmic drug delivery device of claim 7 , wherein said hydrogel is formulated to bioerode and release said pharmaceutically active agent at a controlled rate.
9. The ophthalmic drug delivery device of claim 7 , wherein said pharmaceutically active agent diffuses through said hydrogel at a controlled rate.
10. The ophthalmic drug delivery device of claim 1 , further comprising a retaining member extending from said body proximate said opening, and wherein said retaining member helps to retain said inner core in said well.
11. The ophthalmic drug delivery device of claim 10 , wherein said retaining member comprises a rim at least partially disposed around said opening.
12. The ophthalmic drug delivery device of any one of claims 1-11, wherein said pharmaceutically active agent comprises a compound selected from the group consisting of 4,9(11)-Pregnadien-17α,21-diol-3,20-dione and 4,9(11)-Pregnadien-17α,21-diol-3,20-dione-21-acetate.
13. The ophthalmic drug delivery device of any one of claims 1-11, wherein said pharmaceutically active agent comprises eliprodil.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/957,910 US20050112175A1 (en) | 1999-10-21 | 2004-10-04 | Drug delivery device |
US11/567,892 US7943162B2 (en) | 1999-10-21 | 2006-12-07 | Drug delivery device |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16067399P | 1999-10-21 | 1999-10-21 | |
US9660000A | 2000-09-12 | 2000-09-12 | |
US10/186,960 US6808719B2 (en) | 1999-10-21 | 2002-07-01 | Drug delivery device |
US10/957,910 US20050112175A1 (en) | 1999-10-21 | 2004-10-04 | Drug delivery device |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/186,960 Continuation US6808719B2 (en) | 1999-10-21 | 2002-07-01 | Drug delivery device |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/567,892 Continuation-In-Part US7943162B2 (en) | 1999-10-21 | 2006-12-07 | Drug delivery device |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050112175A1 true US20050112175A1 (en) | 2005-05-26 |
Family
ID=22577913
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/660,000 Expired - Lifetime US6413540B1 (en) | 1999-10-21 | 2000-09-12 | Drug delivery device |
US10/186,960 Expired - Lifetime US6808719B2 (en) | 1999-10-21 | 2002-07-01 | Drug delivery device |
US10/957,910 Abandoned US20050112175A1 (en) | 1999-10-21 | 2004-10-04 | Drug delivery device |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/660,000 Expired - Lifetime US6413540B1 (en) | 1999-10-21 | 2000-09-12 | Drug delivery device |
US10/186,960 Expired - Lifetime US6808719B2 (en) | 1999-10-21 | 2002-07-01 | Drug delivery device |
Country Status (22)
Country | Link |
---|---|
US (3) | US6413540B1 (en) |
EP (2) | EP1473003B1 (en) |
JP (1) | JP4837861B2 (en) |
KR (1) | KR100732262B1 (en) |
CN (1) | CN1292721C (en) |
AR (3) | AR026165A1 (en) |
AT (2) | ATE283013T1 (en) |
AU (2) | AU768400B2 (en) |
BR (1) | BR0014929B1 (en) |
CA (1) | CA2383499C (en) |
CY (1) | CY1109489T1 (en) |
DE (2) | DE60016271T2 (en) |
DK (1) | DK1473003T3 (en) |
ES (2) | ES2315598T3 (en) |
HK (2) | HK1048427B (en) |
MX (1) | MXPA02002338A (en) |
PL (1) | PL196988B1 (en) |
PT (2) | PT1473003E (en) |
TR (1) | TR200201047T2 (en) |
TW (1) | TW555575B (en) |
WO (1) | WO2001028472A1 (en) |
ZA (2) | ZA200201188B (en) |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060182781A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
US20060246145A1 (en) * | 2004-04-30 | 2006-11-02 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid containing microparticles |
US20070212397A1 (en) * | 2005-09-15 | 2007-09-13 | Roth Daniel B | Pharmaceutical delivery device and method for providing ocular treatment |
US7589057B2 (en) | 2004-04-30 | 2009-09-15 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
US20100104654A1 (en) * | 2008-10-27 | 2010-04-29 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
US20100278898A1 (en) * | 2004-04-30 | 2010-11-04 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
US8277830B2 (en) | 2009-01-29 | 2012-10-02 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US8486052B2 (en) | 2001-06-12 | 2013-07-16 | The Johns Hopkins University School Of Medicine | Reservoir device for intraocular drug delivery |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
US8900622B1 (en) | 2004-04-30 | 2014-12-02 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US8905963B2 (en) | 2010-08-05 | 2014-12-09 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
US20150104491A1 (en) * | 2010-04-06 | 2015-04-16 | Allergan, Inc. | Sustained-release reservoir implants for intracameral drug delivery |
US9326949B2 (en) | 2004-04-30 | 2016-05-03 | Allergan, Inc. | Method of making oil-in-oil emulsified polymeric implants containing a hypotensive lipid |
US9474756B2 (en) | 2014-08-08 | 2016-10-25 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
US9492315B2 (en) | 2010-08-05 | 2016-11-15 | Forsight Vision4, Inc. | Implantable therapeutic device |
US9526654B2 (en) | 2013-03-28 | 2016-12-27 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
US9775846B2 (en) | 2004-04-30 | 2017-10-03 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
US9883968B2 (en) | 2011-09-16 | 2018-02-06 | Forsight Vision4, Inc. | Fluid exchange apparatus and methods |
US9968603B2 (en) | 2013-03-14 | 2018-05-15 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
US10010448B2 (en) | 2012-02-03 | 2018-07-03 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
EP3449873A1 (en) * | 2006-03-31 | 2019-03-06 | Mati Therapeutics Inc. | Drug delivery structures and compositions for nasolacrimal system |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
US10258503B2 (en) | 2014-07-15 | 2019-04-16 | Forsight Vision4, Inc. | Ocular implant delivery device and method |
US10398592B2 (en) | 2011-06-28 | 2019-09-03 | Forsight Vision4, Inc. | Diagnostic methods and apparatus |
US10406029B2 (en) | 2001-04-07 | 2019-09-10 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US10500091B2 (en) | 2014-11-10 | 2019-12-10 | Forsight Vision4, Inc. | Expandable drug delivery devices and methods of use |
US10617557B2 (en) | 2010-08-05 | 2020-04-14 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
US10874548B2 (en) | 2010-11-19 | 2020-12-29 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US11318043B2 (en) | 2016-04-20 | 2022-05-03 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
US11419759B2 (en) | 2017-11-21 | 2022-08-23 | Forsight Vision4, Inc. | Fluid exchange apparatus for expandable port delivery system and methods of use |
US11432959B2 (en) | 2015-11-20 | 2022-09-06 | Forsight Vision4, Inc. | Porous structures for extended release drug delivery devices |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
US11617680B2 (en) | 2016-04-05 | 2023-04-04 | Forsight Vision4, Inc. | Implantable ocular drug delivery devices |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
Families Citing this family (145)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ509797A (en) * | 1998-07-10 | 2003-11-28 | Univ Sydney | Prophylactic treatments of neovascularisation in macular degeneration using a steroid |
AU767526B2 (en) | 1999-04-26 | 2003-11-13 | Gmp Vision Solutions, Inc. | Trabeculotomy device and method for treating glaucoma |
ATE283013T1 (en) * | 1999-10-21 | 2004-12-15 | Alcon Inc | MEDICATION DELIVERY DEVICE |
US7943162B2 (en) | 1999-10-21 | 2011-05-17 | Alcon, Inc. | Drug delivery device |
US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
US20050119737A1 (en) * | 2000-01-12 | 2005-06-02 | Bene Eric A. | Ocular implant and methods for making and using same |
US6638239B1 (en) | 2000-04-14 | 2003-10-28 | Glaukos Corporation | Apparatus and method for treating glaucoma |
US20020143284A1 (en) * | 2001-04-03 | 2002-10-03 | Hosheng Tu | Drug-releasing trabecular implant for glaucoma treatment |
US7867186B2 (en) | 2002-04-08 | 2011-01-11 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
US7708711B2 (en) | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
AR030345A1 (en) * | 2000-08-14 | 2003-08-20 | Alcon Inc | METHOD OF TREATMENT OF DISORDERS RELATED TO ANGIOGENESIS |
WO2002056863A2 (en) * | 2000-12-29 | 2002-07-25 | Bausch & Lomb Incorporated | Sustained release drug delivery devices |
US6756058B2 (en) | 2001-01-03 | 2004-06-29 | Bausch & Lomb Incorporated | Sustained release drug delivery devices with multiple agents |
WO2002053129A1 (en) * | 2001-01-03 | 2002-07-11 | Bausch & Lomb Incorporated | Sustained release drug delivery devices with prefabricated permeable plugs |
JP2004520900A (en) * | 2001-01-26 | 2004-07-15 | ボシュ・アンド・ロム・インコーポレイテッド | Improved manufacturing method of sustained release drug delivery device |
EP1418868B1 (en) | 2001-04-07 | 2008-03-26 | Glaukos Corporation | Glaucoma stent for glaucoma treatment |
US7488303B1 (en) * | 2002-09-21 | 2009-02-10 | Glaukos Corporation | Ocular implant with anchor and multiple openings |
US7678065B2 (en) | 2001-05-02 | 2010-03-16 | Glaukos Corporation | Implant with intraocular pressure sensor for glaucoma treatment |
AU2002305400A1 (en) | 2001-05-03 | 2002-11-18 | Glaukos Corporation | Medical device and methods of use for glaucoma treatment |
JP2004536631A (en) * | 2001-05-03 | 2004-12-09 | マサチューセッツ・アイ・アンド・イア・インファーマリー | Implantable drug delivery device and use thereof |
EP1409065B1 (en) | 2001-07-23 | 2007-01-17 | Alcon, Inc. | Ophthalmic drug delivery device |
AU2002319606B2 (en) * | 2001-07-23 | 2006-09-14 | Alcon, Inc. | Ophthalmic drug delivery device |
US7331984B2 (en) | 2001-08-28 | 2008-02-19 | Glaukos Corporation | Glaucoma stent for treating glaucoma and methods of use |
US7749528B2 (en) * | 2001-08-29 | 2010-07-06 | Ricardo Azevedo Pontes De Carvalho | Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues |
RU2311892C2 (en) * | 2001-08-29 | 2007-12-10 | КАРВАЛХО Рикардо А. П. ДЕ | Implantable sealable system for one-way delivery of therapeutic preparations to tissues |
US20060034929A1 (en) * | 2001-12-27 | 2006-02-16 | Brubaker Michael J | Sustained release drug delivery devices with prefabricated permeable plugs |
US7186232B1 (en) | 2002-03-07 | 2007-03-06 | Glaukoa Corporation | Fluid infusion methods for glaucoma treatment |
US7951155B2 (en) | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
AU2003236525A1 (en) * | 2002-06-12 | 2003-12-31 | Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California | Injection devices and methods for testing implants and for unimpeded target location testing |
US20070265582A1 (en) * | 2002-06-12 | 2007-11-15 | University Of Southern California | Injection Devices for Unimpeded Target Location Testing |
BR0313546A (en) * | 2002-08-05 | 2005-07-12 | Alcon Inc | Use of anacortave acetate to protect visual acuity in patients with age-related macular degeneration |
DE10238310A1 (en) * | 2002-08-21 | 2004-03-04 | Erich Jaeger Gmbh | electrode assembly |
US20050143363A1 (en) * | 2002-09-29 | 2005-06-30 | Innorx, Inc. | Method for subretinal administration of therapeutics including steroids; method for localizing pharmacodynamic action at the choroid of the retina; and related methods for treatment and/or prevention of retinal diseases |
WO2004073551A2 (en) * | 2003-02-18 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Transscleral drug delivery device and related methods |
JP2006518383A (en) * | 2003-02-20 | 2006-08-10 | アルコン,インコーポレイテッド | Glucocorticoid formulations for treating pathological ocular angiogenesis |
PL378210A1 (en) * | 2003-02-20 | 2006-03-20 | Alcon, Inc. | Use of steroids to treat ocular disorders |
US20050261668A1 (en) * | 2003-03-28 | 2005-11-24 | Bausch & Lomb Incorporated | Drug delivery device |
US20040236343A1 (en) * | 2003-05-23 | 2004-11-25 | Taylor Jon B. | Insertion tool for ocular implant and method for using same |
JP2007500250A (en) * | 2003-06-13 | 2007-01-11 | アルコン,インコーポレイテッド | Nonsteroidal anti-inflammatory drug formulations for treating pathological ocular angiogenesis |
EP1635842A4 (en) * | 2003-06-20 | 2007-04-04 | Alcon Inc | Treatment of amd with combination of ingredients |
US20040265356A1 (en) * | 2003-06-30 | 2004-12-30 | Bausch & Lomb Incorporated | Drug delivery device |
ZA200508654B (en) * | 2003-07-10 | 2007-01-31 | Alcon Inc | Ophthalmic drug delivery device |
JP4869930B2 (en) | 2003-08-26 | 2012-02-08 | ヴィスタ サイエンティフィック エルエルシー | Ophthalmic drug supply device |
ES2388138T3 (en) * | 2003-08-27 | 2012-10-09 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
AU2004274026A1 (en) * | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
US20050136095A1 (en) * | 2003-12-22 | 2005-06-23 | Brian Levy | Drug delivery device with suture ring |
US20050158365A1 (en) * | 2003-12-22 | 2005-07-21 | David Watson | Drug delivery device with mechanical locking mechanism |
US7276050B2 (en) * | 2004-03-02 | 2007-10-02 | Alan Franklin | Trans-scleral drug delivery method and apparatus |
US9549895B2 (en) * | 2004-04-23 | 2017-01-24 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
US20060024350A1 (en) * | 2004-06-24 | 2006-02-02 | Varner Signe E | Biodegradable ocular devices, methods and systems |
US20060110428A1 (en) * | 2004-07-02 | 2006-05-25 | Eugene Dejuan | Methods and devices for the treatment of ocular conditions |
WO2006039459A1 (en) * | 2004-09-30 | 2006-04-13 | Bausch & Lomb Incorporated | Capsule for encasing tablets for surgical insertion into the human body |
US20060134162A1 (en) * | 2004-12-16 | 2006-06-22 | Larson Christopher W | Methods for fabricating a drug delivery device |
US20060134176A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
KR101387456B1 (en) | 2005-02-09 | 2014-04-21 | 산텐 세이야꾸 가부시키가이샤 | Liquid formulations for treatment of diseases or conditions |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
WO2006110487A1 (en) * | 2005-04-08 | 2006-10-19 | Surmodics, Inc. | Sustained release implants for subretinal delivery |
PL1919290T3 (en) * | 2005-07-12 | 2014-06-30 | Ampio Pharmaceuticals Inc | Methods and products for treatment of diseases |
US20100003297A1 (en) * | 2005-08-11 | 2010-01-07 | Massachusetts Institute Of Technology | Implantable Drug Delivery Device and Methods of Treating Male Genitourinary and Surrounding Tissues |
US20070100199A1 (en) * | 2005-11-03 | 2007-05-03 | Lilip Lau | Apparatus and method of delivering biomaterial to the heart |
WO2007047626A1 (en) * | 2005-10-14 | 2007-04-26 | Alcon, Inc. | Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis |
EP2001438A2 (en) | 2006-02-09 | 2008-12-17 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
DK2001466T3 (en) | 2006-03-23 | 2016-02-29 | Santen Pharmaceutical Co Ltd | LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES |
US20070293807A1 (en) * | 2006-05-01 | 2007-12-20 | Lynch Mary G | Dual drainage pathway shunt device and method for treating glaucoma |
JP4829345B2 (en) * | 2006-05-04 | 2011-12-07 | カフマン、ハーバート | Methods, devices, and systems for administering therapeutic agents to the eye |
US7981096B2 (en) * | 2006-05-12 | 2011-07-19 | David Castillejos | Optic nerve head implant and medication delivery system |
SG138567A1 (en) * | 2006-06-21 | 2008-01-28 | Johnson & Johnson Vision Care | Punctal plugs for the delivery of active agents |
US8852256B2 (en) | 2010-11-15 | 2014-10-07 | Aquesys, Inc. | Methods for intraocular shunt placement |
US8663303B2 (en) | 2010-11-15 | 2014-03-04 | Aquesys, Inc. | Methods for deploying an intraocular shunt from a deployment device and into an eye |
US10085884B2 (en) | 2006-06-30 | 2018-10-02 | Aquesys, Inc. | Intraocular devices |
US8308701B2 (en) | 2010-11-15 | 2012-11-13 | Aquesys, Inc. | Methods for deploying intraocular shunts |
US8721702B2 (en) | 2010-11-15 | 2014-05-13 | Aquesys, Inc. | Intraocular shunt deployment devices |
US20120123316A1 (en) | 2010-11-15 | 2012-05-17 | Aquesys, Inc. | Intraocular shunts for placement in the intra-tenon's space |
EP2043572B1 (en) | 2006-06-30 | 2014-12-31 | Aquesys Inc. | Apparatus for relieving pressure in an organ |
US8506515B2 (en) | 2006-11-10 | 2013-08-13 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US20100034808A1 (en) * | 2006-11-21 | 2010-02-11 | Toru Nakazawa | Compositions and methods for preserving cells of the eye |
US20080140024A1 (en) * | 2006-12-08 | 2008-06-12 | Yoseph Yaacobi | Drug delivery device |
WO2008076544A2 (en) * | 2006-12-18 | 2008-06-26 | Alcon Research, Ltd. | Devices and methods for ophthalmic drug delivery |
US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
ES2921527T3 (en) | 2009-06-03 | 2022-08-29 | Forsight Vision5 Inc | Anterior segment drug delivery |
DE202010017530U1 (en) | 2009-06-22 | 2012-03-28 | Dmi Acquisition Corp. | Danazol compound for the treatment of diseases |
CA2765883A1 (en) * | 2009-06-22 | 2010-12-29 | Dmi Acquisition Corp. | Methods and products for treatment of diseases |
US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
WO2011133964A2 (en) | 2010-04-23 | 2011-10-27 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells |
WO2011146483A1 (en) | 2010-05-17 | 2011-11-24 | Aerie Pharmaceuticals, Inc. | Drug delivery devices for delivery of ocular therapeutic agents |
US20120109054A1 (en) * | 2010-10-29 | 2012-05-03 | Vista Scientific Llc | Devices with an erodible surface for delivering at least one active agent to tissue over a prolonged period of time |
WO2012061045A2 (en) | 2010-11-01 | 2012-05-10 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving retinal ganglion cells |
US10842671B2 (en) | 2010-11-15 | 2020-11-24 | Aquesys, Inc. | Intraocular shunt placement in the suprachoroidal space |
US9107816B2 (en) * | 2011-02-04 | 2015-08-18 | Taris Biomedical Llc | Implantable device for controlled dissolution and diffusion of low solubility drug |
US20150005254A1 (en) | 2011-06-27 | 2015-01-01 | Massachusetts Eye And Ear Infirmary | Methods for treating ocular inflammatory disorders |
US9724357B2 (en) | 2011-08-15 | 2017-08-08 | Massachusetts Eye & Ear Infirmary | Methods for preserving photoreceptor cell viability following retinal detachment |
EP3659495B1 (en) | 2011-09-13 | 2022-12-14 | Dose Medical Corporation | Intraocular physiological sensor |
WO2013040238A2 (en) | 2011-09-13 | 2013-03-21 | Vista Scientific Llc | Sustained release ocular drug delivery devices and methods of manufacture |
RU2740680C2 (en) | 2011-09-14 | 2021-01-19 | Форсайт Вижн5, Инк. | Eye inserter device and methods |
CA2888805C (en) | 2011-10-21 | 2020-07-14 | Massachusetts Eye And Ear Infirmary | Methods and compositions for promoting axon regeneration and nerve function |
US9610195B2 (en) | 2013-02-27 | 2017-04-04 | Aquesys, Inc. | Intraocular shunt implantation methods and devices |
US9808373B2 (en) | 2013-06-28 | 2017-11-07 | Aquesys, Inc. | Intraocular shunt implantation |
US8765210B2 (en) | 2011-12-08 | 2014-07-01 | Aquesys, Inc. | Systems and methods for making gelatin shunts |
US8852136B2 (en) * | 2011-12-08 | 2014-10-07 | Aquesys, Inc. | Methods for placing a shunt into the intra-scleral space |
US10080682B2 (en) | 2011-12-08 | 2018-09-25 | Aquesys, Inc. | Intrascleral shunt placement |
EP2708209A1 (en) * | 2012-09-13 | 2014-03-19 | AJL Ophthalmic, S.A. | Scleral epimacular implant |
PT2911623T (en) | 2012-10-26 | 2019-11-21 | Forsight Vision5 Inc | Ophthalmic system for sustained release of drug to eye |
EP2914225B1 (en) * | 2012-11-01 | 2021-02-17 | Poway Retinal Technologies LLC | Retinal repair device |
KR20150105355A (en) | 2012-12-19 | 2015-09-16 | 앰피오 파마슈티컬스 인코퍼레이티드 | Method for treatment of diseases |
US9745558B2 (en) | 2013-02-18 | 2017-08-29 | Vegenics Pty Limited | VEGFR-3 ligand binding molecules and uses thereof |
US10159600B2 (en) | 2013-02-19 | 2018-12-25 | Aquesys, Inc. | Adjustable intraocular flow regulation |
TW201507749A (en) | 2013-03-11 | 2015-03-01 | Sanofi Aventis Deutschland | Assembly for a drug delivery device |
US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US10098836B2 (en) * | 2013-05-02 | 2018-10-16 | Retina Foundation Of The Southwest | Method for forming a molded two-layer ocular implant |
CN105431204A (en) | 2013-07-12 | 2016-03-23 | 奥普索特克公司 | Methods for treating or preventing ophthalmological conditions |
DK3066201T3 (en) | 2013-11-07 | 2018-06-06 | Editas Medicine Inc | CRISPR-RELATED PROCEDURES AND COMPOSITIONS WITH LEADING GRADES |
BR122020011777B1 (en) | 2013-11-14 | 2022-01-25 | AqueSys, Inc | Insertion device for the treatment of glaucoma |
EP3089748A4 (en) | 2014-01-02 | 2017-09-27 | Massachusetts Eye & Ear Infirmary | Treating ocular neovascularization |
EP3114227B1 (en) | 2014-03-05 | 2021-07-21 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
US11141493B2 (en) | 2014-03-10 | 2021-10-12 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
US11339437B2 (en) | 2014-03-10 | 2022-05-24 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
EP3553176A1 (en) | 2014-03-10 | 2019-10-16 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) |
EP3981876A1 (en) | 2014-03-26 | 2022-04-13 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating sickle cell disease |
EP3283004A4 (en) | 2015-04-13 | 2018-12-05 | Forsight Vision5, Inc. | Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent |
AU2016253150B2 (en) | 2015-04-24 | 2022-04-21 | Editas Medicine, Inc. | Evaluation of Cas9 molecule/guide RNA molecule complexes |
WO2016187426A1 (en) | 2015-05-19 | 2016-11-24 | Amorphex Therapeutics Llc | A device that delivers a sustained low-dose of a myopia-suppressing drug |
NZ737997A (en) | 2015-06-03 | 2019-03-29 | Aquesys Inc | Ab externo intraocular shunt placement |
CN109312338B (en) | 2015-10-30 | 2022-09-27 | 爱迪塔斯医药公司 | CRISPR/CAS related methods and compositions for treating herpes simplex virus |
EP3433364A1 (en) | 2016-03-25 | 2019-01-30 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency |
BR112018074389A2 (en) | 2016-06-02 | 2019-03-06 | Aquesys, Inc. | intraocular drug shipment |
BR112019001887A2 (en) | 2016-08-02 | 2019-07-09 | Editas Medicine Inc | compositions and methods for treating cep290-associated disease |
CA3032153A1 (en) | 2016-08-19 | 2018-02-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration |
EP3532616A1 (en) | 2016-10-28 | 2019-09-04 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating herpes simplex virus |
JP2020514407A (en) | 2017-01-24 | 2020-05-21 | マクリーゲン, インク.Macregen, Inc. | Treatment of age-related macular degeneration and other eye diseases using apolipoprotein mimetics |
WO2018161035A1 (en) | 2017-03-03 | 2018-09-07 | Macregen, Inc. | Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents |
WO2018170184A1 (en) | 2017-03-14 | 2018-09-20 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
WO2018204848A1 (en) | 2017-05-05 | 2018-11-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Ocular applications of matrix bound vesicles (mbvs) |
EP3622070A2 (en) | 2017-05-10 | 2020-03-18 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
WO2019018350A1 (en) | 2017-07-17 | 2019-01-24 | Keith Roizman | Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases |
US11246753B2 (en) | 2017-11-08 | 2022-02-15 | Aquesys, Inc. | Manually adjustable intraocular flow regulation |
EP3758736B1 (en) | 2018-03-02 | 2024-05-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Il-34 for use in a method of treating retinal inflammation and neurodegeneration |
US11135089B2 (en) | 2018-03-09 | 2021-10-05 | Aquesys, Inc. | Intraocular shunt inserter |
US10952898B2 (en) | 2018-03-09 | 2021-03-23 | Aquesys, Inc. | Intraocular shunt inserter |
KR20210133993A (en) | 2019-02-25 | 2021-11-08 | 에디타스 메디신, 인코포레이티드 | CRISPR/RNA-guided nuclease-related methods and compositions for treating RHO-associated autosomal-dominant retinitis pigmentosa (ADRP) |
EP4090381A1 (en) | 2020-01-17 | 2022-11-23 | The United States of America, as represented by the Secretary, Department of Health and Human Services | <smallcaps/>? ? ?crx-? ? ? ? ?gene therapy for treatment ofautosomal dominant retinopathies |
AU2021300425A1 (en) | 2020-07-02 | 2023-02-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cyclic compounds for use in treating retinal degeneration |
WO2022221741A1 (en) | 2021-04-16 | 2022-10-20 | Editas Medicine, Inc. | Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp) |
CN115737892A (en) * | 2022-11-21 | 2023-03-07 | 诺莱生物医学科技有限公司 | Elastic dressing carrying repair matrix and preparation method thereof |
Citations (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3416530A (en) * | 1966-03-02 | 1968-12-17 | Richard A. Ness | Eyeball medication dispensing tablet |
US3828777A (en) * | 1971-11-08 | 1974-08-13 | Alza Corp | Microporous ocular device |
US4014335A (en) * | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
US4014725A (en) * | 1975-03-27 | 1977-03-29 | Union Carbide Corporation | Method of making carbon cloth from pitch based fiber |
US4300557A (en) * | 1980-01-07 | 1981-11-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating intraocular malignancies |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
US4946450A (en) * | 1989-04-18 | 1990-08-07 | Biosource Genetics Corporation | Glucan/collagen therapeutic eye shields |
US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
US5147647A (en) * | 1986-10-02 | 1992-09-15 | Sohrab Darougar | Ocular insert for the fornix |
US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
US5178635A (en) * | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
US5322691A (en) * | 1986-10-02 | 1994-06-21 | Sohrab Darougar | Ocular insert with anchoring protrusions |
US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
US5403901A (en) * | 1990-11-07 | 1995-04-04 | Nestle S.A. | Flexible, high refractive index polymers |
US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5466466A (en) * | 1989-02-18 | 1995-11-14 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Therapeutic system for the retarded and controlled transdermal or transmucous administration of active substrates II |
US5516522A (en) * | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
US5632984A (en) * | 1993-07-22 | 1997-05-27 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
US5679666A (en) * | 1991-11-22 | 1997-10-21 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids |
US5710165A (en) * | 1994-07-06 | 1998-01-20 | Synthelabo | Use of polyamine antagonists for the treatment of glaucoma |
US5725493A (en) * | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
US5743274A (en) * | 1996-03-18 | 1998-04-28 | Peyman; Gholam A. | Macular bandage for use in the treatment of subretinal neovascular members |
US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
US5797898A (en) * | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
US5824073A (en) * | 1996-03-18 | 1998-10-20 | Peyman; Gholam A. | Macular indentor for use in the treatment of subretinal neovascular membranes |
US5836935A (en) * | 1994-11-10 | 1998-11-17 | Ashton; Paul | Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body |
US5883108A (en) * | 1995-11-17 | 1999-03-16 | Alcon Laboratories, Inc. | Combination therapy for treating glaucoma |
US5902598A (en) * | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
US5904144A (en) * | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
US5916584A (en) * | 1994-10-25 | 1999-06-29 | Daratech Proprietary Limited | Controlled release container with core and outer shell |
US6074661A (en) * | 1997-08-11 | 2000-06-13 | Allergan Sales, Inc. | Sterile bioerodible occular implant device with a retinoid for improved biocompatability |
US6120460A (en) * | 1996-09-04 | 2000-09-19 | Abreu; Marcio Marc | Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions |
US6146366A (en) * | 1998-11-03 | 2000-11-14 | Ras Holding Corp | Device for the treatment of macular degeneration and other eye disorders |
US6217895B1 (en) * | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
US6413540B1 (en) * | 1999-10-21 | 2002-07-02 | Alcon Universal Ltd. | Drug delivery device |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4759746A (en) * | 1987-05-14 | 1988-07-26 | Straus Jeffrey G | Retro-bulbar needle |
DE4022553A1 (en) * | 1990-07-16 | 1992-01-23 | Hund Helmut Gmbh | Medical contact lens - with recess contg. therapeutically or diagnostically active substance |
FR2690846B1 (en) | 1992-05-05 | 1995-07-07 | Aiache Jean Marc | GALENIC FORM FOR EYE ADMINISTRATION AND METHOD OF PREPARATION. |
WO1994005257A1 (en) | 1992-09-08 | 1994-03-17 | Allergan, Inc. | Sustained release of ophthalmic drugs from a soluble polymer drug delivery vehicle |
JPH09511507A (en) | 1994-04-04 | 1997-11-18 | フリーマン,ウイリアム・アール | Use of phosphonyl methoxyalkyl nucleosides to treat elevated intraocular pressure |
US5466233A (en) | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
CN2219115Y (en) * | 1994-08-31 | 1996-02-07 | 程康 | Pulse medicine therapeutic apparatus for myopia |
CN1283324C (en) | 1995-05-14 | 2006-11-08 | 奥普通诺尔有限公司 | Intraocular implant, delivery device, and method of implantation |
AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
JP3309175B2 (en) | 1996-03-25 | 2002-07-29 | 参天製薬株式会社 | Scleral plug containing proteinaceous drug |
ZA9710342B (en) * | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
DK0973499T3 (en) * | 1997-03-31 | 2003-11-17 | Alza Corp | Implantable diffusion delivery system |
US6066671A (en) | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
EP1061913B1 (en) | 1998-03-13 | 2007-06-27 | The Johns Hopkins University School Of Medicine | The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy |
DE19847192A1 (en) | 1998-10-13 | 2000-04-27 | Wella Ag | Colorant for fibers, especially human hair, contains 4-nitrophenyl-N-heterocyclic, -cycloalkane, -alkoxyalkane or -amine compound |
US6399655B1 (en) | 1998-12-22 | 2002-06-04 | Johns Hopkins University, School Of Medicine | Method for the prophylactic treatment of cataracts |
-
2000
- 2000-09-12 AT AT00961836T patent/ATE283013T1/en active
- 2000-09-12 CN CNB008131864A patent/CN1292721C/en not_active Expired - Fee Related
- 2000-09-12 PL PL355263A patent/PL196988B1/en not_active IP Right Cessation
- 2000-09-12 DE DE60016271T patent/DE60016271T2/en not_active Expired - Lifetime
- 2000-09-12 MX MXPA02002338A patent/MXPA02002338A/en active IP Right Grant
- 2000-09-12 ES ES04018677T patent/ES2315598T3/en not_active Expired - Lifetime
- 2000-09-12 AU AU73733/00A patent/AU768400B2/en not_active Ceased
- 2000-09-12 TR TR2002/01047T patent/TR200201047T2/en unknown
- 2000-09-12 EP EP04018677A patent/EP1473003B1/en not_active Expired - Lifetime
- 2000-09-12 DE DE60040876T patent/DE60040876D1/en not_active Expired - Lifetime
- 2000-09-12 AT AT04018677T patent/ATE414494T1/en active
- 2000-09-12 CA CA002383499A patent/CA2383499C/en not_active Expired - Fee Related
- 2000-09-12 BR BRPI0014929-2A patent/BR0014929B1/en not_active IP Right Cessation
- 2000-09-12 WO PCT/US2000/024983 patent/WO2001028472A1/en active IP Right Grant
- 2000-09-12 JP JP2001531069A patent/JP4837861B2/en not_active Expired - Fee Related
- 2000-09-12 EP EP00961836A patent/EP1221917B1/en not_active Expired - Lifetime
- 2000-09-12 KR KR1020027005020A patent/KR100732262B1/en not_active IP Right Cessation
- 2000-09-12 ES ES00961836T patent/ES2231257T3/en not_active Expired - Lifetime
- 2000-09-12 US US09/660,000 patent/US6413540B1/en not_active Expired - Lifetime
- 2000-09-12 DK DK04018677T patent/DK1473003T3/en active
- 2000-09-12 PT PT04018677T patent/PT1473003E/en unknown
- 2000-09-12 PT PT00961836T patent/PT1221917E/en unknown
- 2000-10-03 AR ARP000105210A patent/AR026165A1/en active IP Right Grant
- 2000-10-05 TW TW089120788A patent/TW555575B/en not_active IP Right Cessation
-
2002
- 2002-02-12 ZA ZA200201188A patent/ZA200201188B/en unknown
- 2002-02-12 ZA ZA200201189A patent/ZA200201189B/en unknown
- 2002-07-01 US US10/186,960 patent/US6808719B2/en not_active Expired - Lifetime
- 2002-11-15 HK HK02108313.1A patent/HK1048427B/en not_active IP Right Cessation
-
2003
- 2003-03-25 AR ARP030101035A patent/AR039132A2/en unknown
- 2003-03-25 AR ARP030101034A patent/AR039131A2/en unknown
-
2004
- 2004-03-02 AU AU2004200908A patent/AU2004200908B2/en not_active Ceased
- 2004-10-04 US US10/957,910 patent/US20050112175A1/en not_active Abandoned
-
2005
- 2005-03-08 HK HK05102024.1A patent/HK1072177A1/en not_active IP Right Cessation
-
2009
- 2009-01-22 CY CY20091100083T patent/CY1109489T1/en unknown
Patent Citations (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3416530A (en) * | 1966-03-02 | 1968-12-17 | Richard A. Ness | Eyeball medication dispensing tablet |
US3828777A (en) * | 1971-11-08 | 1974-08-13 | Alza Corp | Microporous ocular device |
US4014725A (en) * | 1975-03-27 | 1977-03-29 | Union Carbide Corporation | Method of making carbon cloth from pitch based fiber |
US4014335A (en) * | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
US4300557A (en) * | 1980-01-07 | 1981-11-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating intraocular malignancies |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US5147647A (en) * | 1986-10-02 | 1992-09-15 | Sohrab Darougar | Ocular insert for the fornix |
US5322691A (en) * | 1986-10-02 | 1994-06-21 | Sohrab Darougar | Ocular insert with anchoring protrusions |
US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
US5466466A (en) * | 1989-02-18 | 1995-11-14 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Therapeutic system for the retarded and controlled transdermal or transmucous administration of active substrates II |
US4946450A (en) * | 1989-04-18 | 1990-08-07 | Biosource Genetics Corporation | Glucan/collagen therapeutic eye shields |
US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
US5403901A (en) * | 1990-11-07 | 1995-04-04 | Nestle S.A. | Flexible, high refractive index polymers |
US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
US5679666A (en) * | 1991-11-22 | 1997-10-21 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids |
US5300114A (en) * | 1992-05-04 | 1994-04-05 | Allergan, Inc. | Subconjunctival implants for ocular drug delivery |
US5476511A (en) * | 1992-05-04 | 1995-12-19 | Allergan, Inc. | Subconjunctival implants for ocular drug delivery |
US5178635A (en) * | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
US5632984A (en) * | 1993-07-22 | 1997-05-27 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5766242A (en) * | 1993-11-15 | 1998-06-16 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5824072A (en) * | 1993-11-15 | 1998-10-20 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5516522A (en) * | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
US5710165A (en) * | 1994-07-06 | 1998-01-20 | Synthelabo | Use of polyamine antagonists for the treatment of glaucoma |
US5916584A (en) * | 1994-10-25 | 1999-06-29 | Daratech Proprietary Limited | Controlled release container with core and outer shell |
US5836935A (en) * | 1994-11-10 | 1998-11-17 | Ashton; Paul | Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body |
US5830173A (en) * | 1994-12-12 | 1998-11-03 | Avery; Robert Logan | Intravitreal medicine delivery |
US5725493A (en) * | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
US6001386A (en) * | 1995-09-27 | 1999-12-14 | University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
US5883108A (en) * | 1995-11-17 | 1999-03-16 | Alcon Laboratories, Inc. | Combination therapy for treating glaucoma |
US6126687A (en) * | 1996-03-18 | 2000-10-03 | Peyman; Gholam A. | Macular bandage for use in the treatment of subretinal neovascular membranes |
US5743274A (en) * | 1996-03-18 | 1998-04-28 | Peyman; Gholam A. | Macular bandage for use in the treatment of subretinal neovascular members |
US5824073A (en) * | 1996-03-18 | 1998-10-20 | Peyman; Gholam A. | Macular indentor for use in the treatment of subretinal neovascular membranes |
US5904144A (en) * | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
US5797898A (en) * | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
US6120460A (en) * | 1996-09-04 | 2000-09-19 | Abreu; Marcio Marc | Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions |
US6110485A (en) * | 1997-08-11 | 2000-08-29 | Allergan Sales, Inc. | Sterile bioerodible implant device with a retinoid for improved biocompatability |
US6074661A (en) * | 1997-08-11 | 2000-06-13 | Allergan Sales, Inc. | Sterile bioerodible occular implant device with a retinoid for improved biocompatability |
US5902598A (en) * | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
US6146366A (en) * | 1998-11-03 | 2000-11-14 | Ras Holding Corp | Device for the treatment of macular degeneration and other eye disorders |
US6217895B1 (en) * | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
US6413540B1 (en) * | 1999-10-21 | 2002-07-02 | Alcon Universal Ltd. | Drug delivery device |
US6808719B2 (en) * | 1999-10-21 | 2004-10-26 | Alcon, Inc. | Drug delivery device |
Cited By (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10406029B2 (en) | 2001-04-07 | 2019-09-10 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US10470924B2 (en) | 2001-06-12 | 2019-11-12 | The Johns Hopkins University | Reservoir device for intraocular drug delivery |
US9180046B2 (en) | 2001-06-12 | 2015-11-10 | The Johns Hopkins University School Of Medicine | Reservoir device for intraocular drug delivery |
US9522082B2 (en) | 2001-06-12 | 2016-12-20 | The Johns Hopkins University | Reservoir device for intraocular drug delivery |
US8486052B2 (en) | 2001-06-12 | 2013-07-16 | The Johns Hopkins University School Of Medicine | Reservoir device for intraocular drug delivery |
US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
US10328086B2 (en) | 2004-04-30 | 2019-06-25 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US20060182781A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
US20100278898A1 (en) * | 2004-04-30 | 2010-11-04 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
US9669039B2 (en) | 2004-04-30 | 2017-06-06 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US7589057B2 (en) | 2004-04-30 | 2009-09-15 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
US9707238B2 (en) | 2004-04-30 | 2017-07-18 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
US10406168B2 (en) | 2004-04-30 | 2019-09-10 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US10398707B2 (en) | 2004-04-30 | 2019-09-03 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
US8900622B1 (en) | 2004-04-30 | 2014-12-02 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US10864218B2 (en) | 2004-04-30 | 2020-12-15 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US9750751B2 (en) | 2004-04-30 | 2017-09-05 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US10064872B2 (en) | 2004-04-30 | 2018-09-04 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
US9775846B2 (en) | 2004-04-30 | 2017-10-03 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
US9101583B2 (en) | 2004-04-30 | 2015-08-11 | Allergan, Inc. | Microparticles manufactured in an oil-in-water process comprising a prostamide |
US20060246145A1 (en) * | 2004-04-30 | 2006-11-02 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid containing microparticles |
US9326949B2 (en) | 2004-04-30 | 2016-05-03 | Allergan, Inc. | Method of making oil-in-oil emulsified polymeric implants containing a hypotensive lipid |
US9393223B2 (en) | 2004-04-30 | 2016-07-19 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US20070212397A1 (en) * | 2005-09-15 | 2007-09-13 | Roth Daniel B | Pharmaceutical delivery device and method for providing ocular treatment |
EP3449873A1 (en) * | 2006-03-31 | 2019-03-06 | Mati Therapeutics Inc. | Drug delivery structures and compositions for nasolacrimal system |
US20100104654A1 (en) * | 2008-10-27 | 2010-04-29 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
US10813788B2 (en) | 2009-01-29 | 2020-10-27 | Forsight Vision4, Inc. | Implantable therapeutic device |
US11642310B2 (en) | 2009-01-29 | 2023-05-09 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US10656152B2 (en) | 2009-01-29 | 2020-05-19 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US8808727B2 (en) | 2009-01-29 | 2014-08-19 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US9417238B2 (en) | 2009-01-29 | 2016-08-16 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US9066779B2 (en) | 2009-01-29 | 2015-06-30 | Forsight Vision4, Inc. | Implantable therapeutic device |
US9851351B2 (en) | 2009-01-29 | 2017-12-26 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US8399006B2 (en) | 2009-01-29 | 2013-03-19 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US8298578B2 (en) | 2009-01-29 | 2012-10-30 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US8277830B2 (en) | 2009-01-29 | 2012-10-02 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US8795712B2 (en) | 2009-01-29 | 2014-08-05 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US11426306B2 (en) | 2009-05-18 | 2022-08-30 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
US20150104491A1 (en) * | 2010-04-06 | 2015-04-16 | Allergan, Inc. | Sustained-release reservoir implants for intracameral drug delivery |
US9033911B2 (en) | 2010-08-05 | 2015-05-19 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
US11786396B2 (en) | 2010-08-05 | 2023-10-17 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
US11679027B2 (en) | 2010-08-05 | 2023-06-20 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
US10265215B2 (en) | 2010-08-05 | 2019-04-23 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
US8905963B2 (en) | 2010-08-05 | 2014-12-09 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
US9861521B2 (en) | 2010-08-05 | 2018-01-09 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
US10617557B2 (en) | 2010-08-05 | 2020-04-14 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
US9492315B2 (en) | 2010-08-05 | 2016-11-15 | Forsight Vision4, Inc. | Implantable therapeutic device |
US10874548B2 (en) | 2010-11-19 | 2020-12-29 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
US11065151B2 (en) | 2010-11-19 | 2021-07-20 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
US10398592B2 (en) | 2011-06-28 | 2019-09-03 | Forsight Vision4, Inc. | Diagnostic methods and apparatus |
US11813196B2 (en) | 2011-06-28 | 2023-11-14 | Forsight Vision4, Inc. | Diagnostic methods and apparatus |
US9883968B2 (en) | 2011-09-16 | 2018-02-06 | Forsight Vision4, Inc. | Fluid exchange apparatus and methods |
US10653554B2 (en) | 2011-09-16 | 2020-05-19 | Forsight Vision4, Inc. | Fluid exchange apparatus and methods |
US10603209B2 (en) | 2012-02-03 | 2020-03-31 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
US10010448B2 (en) | 2012-02-03 | 2018-07-03 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
US9968603B2 (en) | 2013-03-14 | 2018-05-15 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
US11253394B2 (en) | 2013-03-15 | 2022-02-22 | Dose Medical Corporation | Controlled drug delivery ocular implants and methods of using same |
US9526654B2 (en) | 2013-03-28 | 2016-12-27 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
US10398593B2 (en) | 2013-03-28 | 2019-09-03 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
US11510810B2 (en) | 2013-03-28 | 2022-11-29 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US11337853B2 (en) | 2014-07-15 | 2022-05-24 | Forsight Vision4, Inc. | Ocular implant delivery device and method |
US10258503B2 (en) | 2014-07-15 | 2019-04-16 | Forsight Vision4, Inc. | Ocular implant delivery device and method |
US9895369B2 (en) | 2014-08-08 | 2018-02-20 | Forsight Vision4, Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
US10765677B2 (en) | 2014-08-08 | 2020-09-08 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
US9474756B2 (en) | 2014-08-08 | 2016-10-25 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
US10363255B2 (en) | 2014-08-08 | 2019-07-30 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
US11110001B2 (en) | 2014-11-10 | 2021-09-07 | Forsight Vision4, Inc. | Expandable drug delivery devices and methods of use |
US10500091B2 (en) | 2014-11-10 | 2019-12-10 | Forsight Vision4, Inc. | Expandable drug delivery devices and methods of use |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
US11432959B2 (en) | 2015-11-20 | 2022-09-06 | Forsight Vision4, Inc. | Porous structures for extended release drug delivery devices |
US11617680B2 (en) | 2016-04-05 | 2023-04-04 | Forsight Vision4, Inc. | Implantable ocular drug delivery devices |
US11318043B2 (en) | 2016-04-20 | 2022-05-03 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
US11419759B2 (en) | 2017-11-21 | 2022-08-23 | Forsight Vision4, Inc. | Fluid exchange apparatus for expandable port delivery system and methods of use |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6808719B2 (en) | Drug delivery device | |
US7943162B2 (en) | Drug delivery device | |
US6986900B2 (en) | Ophthalmic drug delivery device | |
US6669950B2 (en) | Ophthalmic drug delivery device | |
US7094226B2 (en) | Ophthalmic drug delivery device | |
AU2002319606A1 (en) | Ophthalmic drug delivery device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALCON, INC., SWITZERLAND Free format text: CHANGE OF NAME;ASSIGNOR:ALCON UNIVERSAL LTD.;REEL/FRAME:016963/0321 Effective date: 20020211 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |